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“All you really need to know for the moment is that the universe is a lot more 
complicated than you might think, even if you start from a position of thinking 
it's pretty damn complicated in the first place.”  
 Douglas Adams  
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ABSTRACT 
Prostate cancer (PC) is often a slow-growing and symptom-free disease with good prognosis. 
However, a substantial number will progress, ultimately metastasize if left untreated and finally 
kill the patient. The standard treatment for these stages of PC is androgen deprivation therapy 
(ADT), which generally has an initially good clinical response. However, ADT drives development 
of highly aggressive forms of castration-resistant PC (CRPC) and promote development of bone 
metastases. Thus, early detection of resistance is invaluable considering the incurability of these 
stages once they are established. 
The purpose of the present thesis was to assess the regulation and significance of regulator of G-
protein signaling (RGS2) in PC; with focus on PC progression, and development of CRPC and bone 
metastases. Furthermore, evaluate its potential as a prognostic biomarker for hormone-naïve 
prostate cancer (HNPC) and in association to development and progress of CRPC. This, as the new 
era of treatment options calls for stable reliable biomarkers for adequate treatment decisions.  
The principal findings from this work suggest that, RGS2 was highly expressed in both advanced 
HNPC and CRPC. The significance of this was reflected by the association between high levels of 
RGS2 and poor clinical outcome in both of these stages. Moreover, experimental data suggest 
that RGS2 expression is regulated by hypoxia and HIF1. The implication of different levels of RGS2 
was assessed with RGS2 knockdown in the PC cell line LNCaP. The results show that low and high 
RGS2 expressing PC cells have distinct PC phenotypes, resembling early low-risk tumors and 
advanced PC, respectively. Furthermore, the data suggests that by mediating the effect of 
hypoxia, RGS2 has significant tumor promoting roles in HNPC. Additionally, induced RGS2 
expression, in response to ADT, was found predictive of decreased time to relapse in association 
with resumed androgen-receptor (AR) signaling. The stromal expression of RGS2 display a 
contrasting expression pattern compared to the epithelial, with decreased expression in 
association with more advanced disease, the relevance of this was suggested by a prognostic 
property of stromal RGS2 expression. Finally, high RGS2 expression levels were noticed in human 
PC bone metastases, and found to be essential for the tumor cells ability to establish in the bone, 
as well as endorsing of the sclerotic phenotype that is associated with PC bone metastases. 
In conclusion, the present thesis suggests a tumor-promoting function for RGS2, associated with 
PC progress and development of CRPC and PC bone metastases. Furthermore, the results suggest 
that RGS2 has potential as a prognostic and treatment-predictive biomarker in PC. 
Keywords: Prostate cancer, regulator of G-protein signaling 2, castration-resistance, androgen 
receptor, prostate cancer bone metastases 
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POPULÄRVETENSKAPLIG SAMMANFATTNING  
Prostata cancer (PC) är den vanligaste cancerformen hos män i Sverige och 
även den cancerform som står för flest cancer-relaterade dödsfall. PC har ofta 
ett långsamt symptomfritt förlopp som är begränsat till prostatan, dessa 
tumörer har en mycket god prognos och upptäcks främst via rutinmässiga PSA 
kontroller. I vissa fall utvecklar dock PC ett aggressivt tillväxt mönster och växer 
utanför prostatan i den omkringliggande vävnaden, eller sprider sig vidare till 
andra organ som metastaser. PC är beroende av manligt könshormon 
(androgener) för tillväxt och överlevnad, följaktligen behandlas patienter med 
lokalt aggressiv eller metastaserande sjukdom med medicinsk eller kirurgisk 
kastration, så kallad ”androgendeprivations terapi” (ADT). Behandlingen 
bromsar tumörtillväxten genom att blockera produktionen av manligt 
könshormon från testiklarna. ADT har initialt en mycket god effekt hos de flesta 
patienter, dock är denna effekt begränsad och cancern återupptar sin tillväxt i 
kastrations-resistent form (CRPC). Då det idag inte finns någon botande terapi 
för CRPC är prognosen för dessa patienter mycket dålig och överlevnaden är 
generellt kortare än tre år. Livslängden kan för en del patienter förlängas med 
några år vid insats av tillgängliga livsförlängande behandlingsalternativ. 
Övergången till CRPC är oftast relaterad till fortsatt signalering via androgen 
receptorn (AR) trots pågående ADT. Kastrationsresistens kan cancercellerna 
uppnå genom flertalet mekanismer exempelvis via AR- associerade mekanismer 
där cellen blir oberoende av hormonstimulans för AR aktivitet eller mekanismer 
då även små mängder av androgener är tillräckligt för fortsatt signalering. 
Ytterligare kan tumörcellerna själva börja producera androgener.  
PC metastaserar främst till skelettet och när tumören väl etablerat sig i ben är 
den obotbar. Benmetastaser är förknippade med kraftigt reducerad livskvalité 
till följd av benmetastasernas aggressiva tillväxt och modulering av benet.  
Mekanismerna bakom utvecklingen av avancerad sjukdom, kastrations-
resistens och benmetastaser är till stor del okända. För att bättre kunna 
behandla alla stadier av PC är det viktigt att förstå de biologiska processer som 
driver denna utveckling. I detta avseende har vi studerat proteinet ”regulator of 
G-protein signalling (RGS2)”, för att bestämma dess relevans för PC utveckling 
vid de olika stadierna av sjukdomen, samt för att utvärdera det kliniska värdet 
av RGS2 som prognostiskmarkör. 
RGS2s roll i cancer har inte studerats nämnvärt, och det är relativt få och 
motstridiga rapporter om dess kliniska relevans. I våra studier av obehandlad 
PC, har vi experimentellt visat att vid låga nivåer av RGS2 får PC cellerna 
karaktärsdrag påminnande om de långsamt växande tidiga tumörerna, medan 
 högre nivåer var associerade med en snabbt växande och metastaserande 
tumörtyp. I linje med dessa fynd visade data från kliniska material att höga 
nivåer av RGS2 i tumörvävnaden var associerad med en försämrad överlevnad. 
Förekomsten av RGS2 i tumörangränsande celler uppvisade ett motsatt 
förhållande, och låg förekomst var associerat med lägre överlevnad.  
Vidare studerades RGS2 i kliniska material bestående av CRPC och obehandlade 
tumörer, samt i tumörer från patienter som under kort tid behandlats med 
ADT. Dessa studier visade att nivåerna av RGS2 generellt var högre i CRPC 
jämfört med obehandlade tumörer, dessutom var en hög nivå i CRPC associerat 
med en förkortad överlevnad hos dessa patienter. En hög nivå av RGS2 efter 
påbörjad ADT var associerat med en snabb kastrations-resistent återväxt hos 
dessa patienter. Experimentellt konstaterades RGS2s prognostiska egenskaper 
vara associerade med fortsatt AR signalering. Vidare studier i ett 
patientmaterial bestående av benmetastaser från både obehandlade och CRPC 
patienter, visade generellt höga nivåer av RGS2 i tumörerna, och särskilt höga 
nivåer i CRPC. Experimentella studier visades att RGS2 har stor påverkan på PC 
cellernas förmåga att bilda tumör i ben. RGS2 visades även bidra till 
tumörcellernas stimulerande effekt på osteoblaster, de benbyggande cellerna i 
benet. På detta vis bidrar RGS2 till den generella ben tillväxt som är vanlig hos 
benmetastaser vid PC.  
Sammanfattningsvis beskriver denna avhandling att RGS2 har en relevant 
tumör-främjande roll vid utveckling av avancerad PC och benmetastaser. Vidare 
visades, att höga nivåer av RGS2 i tumör cellerna är associerat med dålig 
prognos i både obehandlad och kastrations-resistent PC, samt att RGS2 i ett 
tidigt skede under behandling med ADT kan prediktera snabb utveckling till 
CRPC. Resultaten visar att RGS2 har potential som prognostisk och 
behandlingsprediktiv biomarkör vid PC. 
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1 INTRODUCTION 
 Cancer 1.1
Cancer is a global cause of death and a universal health problem [1-4]. The term 
cancer is an assemblage of related diseases that originates from different cell 
types of the human body. The majorities of cancers arise in epithelial cells, and 
are designated carcinomas, or adenocarcinoma, when the epithelial cell is 
originating from glandular tissue [5, 6] as in the case of prostate cancer (PC).  
The major dissimilarities between a normal cell and the cancer cell are an 
increased growth rate, loss of differentiation, and ability to escape from 
programmed cell death (apoptosis) and senescence [5, 6]. 
Carcinogenesis, the development of malignant tumors, is a multistep process 
involving not only the tumor epithelial cells but also the surrounding stroma [7-
9]. The longevity and life style of the modern human, permits the accumulation 
of mutations and genomic instability that together leads to the development of 
cancer [10, 11]. 
 Prostate cancer 1.2
Prostate cancer is the most prevalent diagnosed cancer and the second leading 
cause of cancer-associated death in males around the world [2, 3].  
Like most cancers, PC development is associated with the accumulation of 
genetic and epigenetic aberrations over time, thus PC is a disease of the elderly, 
with an average time of diagnosis around the age of 65 years. Although, most 
PC is sporadic, there is a significant increased risk of developing the disease 
with a family history of PC [12-14].  
In addition to genetic predisposition [15], several life style factors have been 
associated with the development of PC [16, 17]. Consistent with multifactorial 
diseases, familial PC has an early onset and often more aggressive course 
compared to sporadic cases [18, 19].  
PC incidence has dramatically increased over the past decades, while PC 
mortality has remained fairly constant, although a small decrease has been 
observed in most countries the last decade. This is most likely mainly associated 
with the introduction of PSA testing, introduced in the late 1980s and now 
widely used in clinical practice [20]. Additionally, with an aging population 
these trends could be expected. 
 The prostate gland and cancer 1.2.1
The prostate is an exocrine gland of the male mammalian reproductive system. 
It can be anatomically divided into three distinct glandular zones, the 
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peripheral, central and transitional zone - the peripheral zone being the largest 
and the predominant site for PC [21, 22].  
The glandular structure of the prostate is composed of epithelial lined acini that 
are encapsulated by the fibrous basal membrane and surrounded by a dense 
fibromuscular stroma. The epithelial bilayer constitute of three distinct cell 
types, luminal, basal and endocrine cells (Figure 1).  
 
Figure 1. Schematic illustration of a cross section of human prostate acinus. The epithelium 
is composed of luminal, basal, intermediate and neuroendocrine cells, separated from the 
surrounding stroma by the fibrous basal membrane. 
The large, columnar luminal cells express the androgen receptor (AR) 
transcription factor, and are strictly androgen-dependent. These cells express 
secretory proteins such as the prostate-specific antigen (PSA) that are secreted 
into the lumen. Outside the luminal layer, lining the basal membrane, are the 
non-secretory committed basal cells. These cells generally express insignificant 
levels of AR, and are not dependent on AR stimulation for survival [23]. 
Additionally, dispersed between the basal cells are AR-negative neuroendocrine 
cells. Like the luminal cells, they are secretory and secrete neuropeptides and 
hormones thought to regulate the development, growth and survival of the 
surrounding epithelial cells [24, 25]. Finally, a population of intermediate cells 
shares common features with luminal, basal and endocrine cells, their 
phenotype and expression profile suggests a hierarchal development of the 
epithelial bilayer [26, 27]. The basal and luminal epithelium both contains small 
population of stem cells, or progenitors that are thought to be able to give rise 
to all epithelial cells [28, 29]. During carcinogenesis, the well-organized 
architecture of the prostate is compromised. The basal layer and membrane 
are disrupted and the luminal secreted proteins, such as PSA, leaks out into the 
surrounding stroma and vasculature. 
Anna Linder 
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1.2.1.1 The epithelial origin of PC 
The pursuit to identify the PC progenitor amongst the epithelial cell types has 
long been a central quest. The prostate carcinomas are heterogeneous, and 
display luminal exocrine, intermediate and neuroendocrine cell phenotypes, 
which has led to controversy regarding the identity of the tumor progenitor.  
At the malignant stage, there is a disruption of the epithelial cell linage and 
subsequently skewing of the cell ratio with an dominance towards a luminal cell 
phenotype [30], in addition most PC are androgen-dependent and secretory, 
thus the luminal cell has long been postulated as the tumor progenitor. 
However, more recently the basal cell has come into spotlight as an alternative 
cell of origin [31-33]. Also a PC stem cell or intermediate cell origin has been 
proposed [34]. 
The stem cell hypothesis suggests that a genetically unstable tumor progenitor 
retains unlimited self-renewal ability, while a subgroup differentiates into 
malignant cells with features of the mature cells of the epithelium [35]. A 
second model proposes a clonal expansion of the tumor progenitor that by 
sequential accumulation of genetic and epigenetic aberrations in the progeny 
leads to the cell heterogeneity seen in PC tumors.  These two models are not 
necessarily mutually exclusive, but might together contribute to the 
heterogeneity and late onset of PC [36, 37].  
1.2.1.2 The stroma 
The heterogeneous prostatic stroma is composed of smooth muscle cells, 
fibroblasts and infiltrating immune cells, that are imbedded in a collagenous 
matrix together with blood vessels, lymphatic vessels and nerves [38].  
AR positive stromal cells, both smooth muscle cells and fibroblasts, have been 
shown to regulate differentiation, growth and survival of the epithelial, cells via 
the production of growth factors – andromedins - in response to AR stimulation 
[39-41]. The stromal cellular composition and expression profile is distinct in 
different prostatic zones; this has been suggested to contribute to the 
predisposition of cancer development in the peripheral zone [38, 42-45].  
Early during tumor development, phenotypic and genotypic alterations of the 
stroma occur – collectively referred to as reactive stroma [46, 47]. These 
alterations are believed to be a response to the disrupted architecture and 
leakiness of the epithelial layer. The changes are similar to wound repair and 
includes matrix remodeling and altered expression of repair-associated growth 
factors and cytokines [48]. During the transition from normal to reactive 
stroma, the smooth muscles cells are replaced by cancer-associated fibroblasts 
(CAFs), myofibroblast and immune cells [47].  
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 Androgens and AR signaling 1.2.2
As a part of the male reproductive system, the prostate is strictly dependent on 
androgens for normal development, maintenance and function. The most 
abundant circulating androgen is testosterone (T), which are mainly produced 
by the testis. The remaining fraction of T comes from precursors, 
dehydroepiandrosterone (DHEA) and androstenedione (AD), produced in the 
adrenal glands and converted to T in peripheral tissue [49]. The production of 
androgens is regulated via the hypothalamic-pituitary-gonadal axis (Figure 2), 
which starts in the brain with the endocrine secretion of gonadotropin-
releasing hormone (GnRH) and corticotrophin (CRH) from the hypothalamus. 
GnRH diffuses into the nearby pituitary, which release luteinzing hormone (LH) 
and adrenocorticotropic hormone (ACTH). LH stimulates the leydig cells of the 
testis to produce testosterone, while ACTH stimulates the release of the 
adrenal androgen precursors’, DHEA and AD.  
Figure 2. The hypothalamic-pituitary-gonadal axis the forward signaling. In addition, 
feedback- loops at every step firmly regulate the release of signaling molecules (not drawn). 
The produced testosterone diffuses into the prostate where it is catalyzed by 
5α-reductase to the more bioactive dihydrotestosterone (DHT). This conversion 
mainly occurs in the stroma but also in the epithelial cells. The effects of 
androgens are mediated by the main prostatic transcription factor, the AR.  
Both T and DHT has the ability to bind AR, however DHT has higher affinity for 
AR and a lower dissociation rate than T and are thus more potent [50, 51].  
Inactivated AR is present in the cytosol where it is stabilized by heat shock 
proteins such as HSP70 and HSP90 [52]. Activation of the AR is a multistep-
process that includes phosphorylation and protein interactions. Simplified 
(Figure 3), AR ligand binding induces a conformational change that results in 
dissociation of bound HSPs. Subsequent homodimerization and 
phosphorylation stabilizes and activates the ligand-receptor complex, which 
Anna Linder 
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thereafter translocate into the nucleus where  it associates with co-regulators 
[53] and RNA polymerase II. The complex modulates gene expression of target 
genes by the binding to specific androgen response elements (AREs) [54, 55]. 
 
 
 
 
 
 
 
 
Figure 3. Schematic illustration of AR activation as described in the text. TM, Transcription 
machinery; RNA polymerase II and additional co-regulators.  
In the normal prostate, binding of androgens to the stromal AR stimulates the 
growth of epithelial cells via paracrine andromedin signaling, while AR 
stimulation in epithelial cells has a suppressive effect by inhibition of the 
andromedin-stimulated proliferation [56]. However, at the malignant stage 
autocrine signaling in the epithelial cells instead has a stimulating effect on 
proliferation and survival [57, 58]. This adaptation could, at least in part, be 
attributed to altered expression of the oncogenic tumor transcription factor 
cMYC, which are down-regulated in response to AR signaling in normal 
epithelial cells, however induced by androgen stimulation in PC cells [59].  
 Prostate cancer pathology and diagnosis 1.2.3
Prostate cancer is diagnosed as localized, locally advanced or metastatic 
disease. The vast majority of identified PC are confined within the prostate, 
referred to as localized [60]. The natural course of PC is generally slow and 
asymptomatic, thus most men die with, not from the disease. In fact, it has 
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been estimated that as many as 80% of males over the age of 80 harbors an 
undiagnosed local foci of PC [61, 62]. Locally advanced PC is characterized by 
invasive growth in the surrounding tissue and is sometimes associated with 
symptoms of the lower urinary tract and hematuria. In metastatic disease PC 
cells has disseminated via the blood or lymphatic circulation and repopulated 
distant sites, mainly bone, but also commonly distant lymph nodes and liver 
[63]. At this stage of PC, symptoms such as bone pain and fractures are 
common.  
Due to the asymptomatic course of local prostate cancer, it is often detected by 
routine PSA blood testing. Following diagnostic investigation includes rectal 
palpation, magnetic resonance imaging (MRI) and ultrasound together with 
sampling of needle biopsies that are evaluated histologically [15, 64]. The 
purpose of these examinations is to identify patients that would benefit from 
continued monitoring e.g. active surveillance [65] or patients that requires 
aggressive treatment.  
In the adult male, PSA are essentially expressed exclusively by prostate 
epithelial cells, including malignant cells. In addition, the majority of prostate 
derived bone metastases express PSA [66]. Thus PSA is an intuitively good 
marker for the detection of both local and metastatic PC. However, the 
architecture of the prostate is compromised also in benign pathologies of the 
prostate, including BPH and prostatitis, therefore the PSA value is not sufficient 
for PC diagnosis [67], and associated with an imminent risk for over-diagnosis 
and over-treatment [68]. The guidelines for PSA advises that: A PSA blood level 
of 0-3 ng/ml is considered normal, above 10 ng/ml is indicative of local tumor 
growth and with a PSA level that exceeds 100 ng/ml, metastatic diseases can be 
suspected [69]. However, PSA does not discriminate between indolent and 
aggressive forms of PC [70, 71].  
For assessment of tumor aggressiveness, histological evaluation is essential. 
The Gleason system is an important tool as it consider the differentiation of the 
tumor as a measurement of aggressiveness with high prognostic accuracy, 
especially for the identification of low risk patients [72]. The Gleason grade 
(GD) classifies tumors on a scale graded 2-5, where 5 is the most malignant 
grade [73]. An overall Gleason score (GS) is calculated from first, the most 
common pattern within all tissue and second, the highest grade observed. 
The most clinically used staging system for prostate cancer is the TNM system. 
TNM summarize the stage of cancer considering the tumor size and/or 
extension (T), lymph node involvement (N) and the presence of distant 
metastasis (M). T is considered on a 1-4 scale, reflecting increasingly large and 
invasive tumors. T1-T2 designates localized PC, while T3-T4 is locally advanced. 
N and M are divided into 0 = negative, 1 = positive or X = not assessed [74]. The 
Anna Linder 
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nature of the metastatic spread are directly correlated to survival, M1 patients 
has a poor prognosis with an average survival of 2-3 years, while N1 patients 
has a median cancer-specific survival of 8 years [15].   
One of the great difficulties when it comes to PC diagnosis is to accurately 
estimate and separate the aggressiveness of the tumor at diagnosis. While the 
majority of PC remains indolent with a slow growing course, others will 
progress to advanced disease. The current clinicopathological variables are 
lacking satisfactory prognostic accuracy, thus the search for new markers are an 
important and ongoing task. 
 Treatment of Prostate cancer 1.2.4
For localized PC, the treatment options include radiation therapy, radical 
prostectomy and active surveillance. The two former are considered curative, 
and are applied when the patient is diagnosed with high-risk tumor and/or has 
a long life expectancy. Radical prostectomy is the most common curative 
treatment used in Sweden [15]. Overall, the risk for relapse after this type of 
treatment is about 30% [75]. Active surveillance is implemented for patients 
with low risk tumors and/or in association with an overall short life expectancy. 
The patient is routinely monitored and curative treatment are applied in case of 
clinical progress [15].  
For locally advanced and metastatic disease the mainstay treatment is surgical 
or chemical castration, the later referred to as androgen deprivation therapy 
(ADT). This treatment regime has been in use since Huggins and Hodges in the 
early 1940s, recognized that PC where androgen-dependent [76]. Today ADT is 
recommended to be in use in combination with other treatments to increase 
survival. For local advanced PC, this includes radiation therapy [77], while 
docetaxel and abirateron/enzalutamide has been shown to increase survival for 
metastatic disease [78]. 
The aim of ADT is to chemically, decrease the level of circulating androgens and 
consequently diminish AR signaling, this is achieved by the administration of 
GnRH agonists or antagonists that targets the hypothalamic–pituitary axis [49], 
thus disrupting the testosterone production in the Leydig cells of the testis. An 
alternative to GnRH agonists/antagonists is surgical castration. The effects of 
androgens can further be suppressed by AR antagonists such as bicalutamide, 
which are administrated in combination with ADT, then referred to as full 
androgen blockade [15]. However, despite initial good clinical response to ADT 
and survival enhancing combination therapies, the majority of patients will 
eventually experience a tumor relapse [78]. 
Generally, Castration-resistant PC (CRPC) remains dependent on AR signaling 
for growth and survival, thus ADT remains as the basis treatment also at this 
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stage [79]. Therapies used in combination with ADT, includes chemotherapy 
and radiation therapy. To bypass the resistance-mechanisms associated with 
the development of CRPC (see resistance-mechanisms), drugs like abiraterone 
acetate (abiraterone in short) and enzalutamide are used in clinic with good 
survival benefit [80]. Abiraterone targets a critical step in testosterone 
synthesis, by the inhibition of CYP17 [81]. Enzalutamide is a multi-mechanistic 
drug, that suppress AR signaling by inhibition of ligand binding, nuclear 
translocation and DNA interaction of activated AR [82]. Apalutamide and 
darolutamide are new drugs with the same mode of action as enzalutamide. A 
common problem with these new treatments is the increased incidence of 
highly aggressive PC upon development of resistance [79, 83]. For prevention 
and delay of cancer-related skeletal events, additional treatment is advised for 
metastatic CRPC, these treatments target the activation of osteoclasts [84].  
 Castration-resistant PC (CRPC) 1.3
Castration-resistant PC (CRPC) are defined by disease progression despite ADT, 
based on the following criteria, continuous rise in PSA (biochemical failure), 
progression of pre-existing disease and/or occurrence of new metastases [85]. 
CRPC is a highly aggressive disease that generally develops within a few years 
following ADT, and despite new treatment options the median survival after PC 
relapse is only 3-4 years [78]. ADT has been shown to induce resistance-
mechanisms that trigger aggressive androgen-independent tumor growth and 
metastasis [86, 87]. Resistance mechanisms to ADT and AR inhibition can be  
divided into three categories - restored AR signaling, AR bypass and complete 
androgen independence [79].  
 Mechanisms of castration resistance 1.3.1
The development of the majority of CRPC is associated resistance-mechanisms 
that enables restored AR-signaling. This is reached by various mechanisms 
including AR amplification, AR mutations, ligand independent AR activation and 
intratumoral steroidogenesis. 
1.3.1.1 AR amplification 
AR amplification and subsequently elevated levels of AR, hypersensitizes the PC 
cells to castration levels of androgens. AR amplification is prominent in CRPC 
but rare in HNPC and thus thought to be treatment dependent [88], this is 
supported by the increased occurrence of AR amplification in response to 
abiraterone and enzalutamide treatment [89]. Increased AR expression is also 
direct associated with ADT in response to transcriptional alterations [90]. 
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1.3.1.2 Gain-of-function AR mutations 
In CRPC, the AR ligand binding domain (LBD) has been recognized as a hotspot 
for mutations, with a frequency of approximately 20-30% of the most abundant 
mutations [91, 92]. At least some of these mutations (e.g. T878A/S) have been 
shown to generate AR promiscuity, that is, it can be stimulated by ligands other 
than androgens [93-95]. 
1.3.1.3 Ligand independent AR activation 
AR variants (ARVs) that lack the AR LBD are yet another common aberration in 
both advanced PC and CRPC. The absence of the LBD, results in a constitutively 
active AR, which are able to enter the nucleus and modulate transcription 
without ligand binding. This feature proposes an important role for ARVs during 
development of resistance, importantly in regard to second-line treatment 
(abiraterone and enzalutamide) [79]. ARVs can be the result of genomic 
alterations of the AR gene [96], or splice variants induced by the selective 
pressure of ADT [97, 98]. Studies of ARV7 has shown that it regulates 
transcription of a unique set of AR-independent genes in addition to AR-
responsive genes, suggesting that, at least, this splice variant has an 
overlapping but distinct role compared to full length-AR in PC cells [4, 99].  
Ligand independent activation of AR can also occur by cross-talk between the 
androgen-signaling pathway and other pathways, leading to the 
phosphorylation and activation of AR in response to interleukins and growth 
factors such as interleukin-6 (IL-6) that activate the STAT3 pathway, or insulin-
like growth factor 1 (IGF-1), HER2, Keratinocyte growth factor (KGF) and 
epidermal growth factor (EGF), which activates the PI3K/AKT and 
phosphorylation of AR in the absence of ligand [79, 100-102]. 
1.3.1.4 Persistent androgens 
ADT targets the secretion of GnRH from the hypothalamus (Figure 2); hence 
exclusively affect the production of androgens in testis. However, physiological 
significant amounts of androgens remain in the tumor despite ADT [79]. The 
primary source of these androgens is the adrenal androgen precursors, mainly 
DHEA-S, which remains high in CRPC, but my also stem from de novo 
steroidogenisis from cholesterol in the tumor [103-105].  Aberrant expression 
of several steroidogenesis-regulating factors has been associated with 
castration-resistance [106], e.g  expression of Steroid 17-alpha-
hydroxylase/17,20 lyase (Cyp17) is  found in all PC and up-regulated in CRPC 
[107]. Cyp17, the target of abiraterone acetate, regulates two steps in the 
conversion of cholesterol to DHEA-S. Another example of altered 
steroidogenesis in CRPC is the up-regulation of steroid-5α-reductase 
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isoenzyme-1 (SRDA1) which facilitates the conversion of adrenal AD [108]. Both 
these alteration enables the bypass of testosterone.  
1.3.1.5 Androgen receptor bypass and true independence 
When the AR is bypassed, the expression of AR target genes are regulated by 
other hormone receptors such as glucocorticoid receptor (GR) that been shown 
to regulate transcription of AR target genes in PC [79]. A minor subset of PC is 
AR negative, and driven by alternative signaling pathways e.g. N-MYC. Like in 
the case of AR bypass, these tumors are unresponsive to the AR-associated 
drugs available. These tumors are often of neuroendocrine or small cell 
carcinoma subtypes [79].  
 Progression of PC  1.4
Several signaling pathways are induced during cancer development and 
progression. These pathways regulate biological processes that lead to 
increased tumor cell proliferation, survival and metastasis in response to 
various stimuli, such as growth factors, interleukins and oncogenic signals 
induced by the demand for adaption under the harsh tumor conditions. 
 Epithelial-mesenchymal transition (EMT) 1.4.1
About 20 years ago, it was first hypothesized that cancerogenesis is related to 
abnormal re-awakening of developmental mechanisms normally restrained to 
organogenesis [109]. During the embryonic development of the prostate, cells 
of the glandular tissue passes through several cycles of epithelial-mesenchymal 
and mesenchymal-epithelial transitions (EMT and MET) to form the epithelial 
layer [110].  
During EMT epithelial cells lose epithelial characteristics and acquire a 
mesenchymal phenotype with increased motility and potential to evade the 
surrounding tissue through loss of adherence to neighboring cells [111, 112]. It 
is a dynamic and reversible biological process, which involves several biological 
pathways and crosstalk between the cells [113-118]. For instance, central 
pathways like wnt, the signal transducer and activator of transcription 3 
(STAT3) and phosphoinositide 3-kinase (PI3K)/AKT pathways has been linked to 
EMT and metastasis [119-121]. In line, these pathways are induced in 
association to PC tumor progression and/or metastasis [120, 122-126]. 
Furthermore, ADT has been shown to induce EMT at an early stage during 
treatment [127]. 
The biological process of EMT is coordinated by transcription factors from the 
SNAIL [128, 129], zinc-finger E-box-binding (ZEB) [130] and TWIST families 
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[131], which modulates the expression of targets genes to promote 
dissemination and invasion [132, 133]. This includes altered expressions of 
cytoskeletal proteins (e.g. vimentin and α-SMA) and proteinases (mainly MMPs) 
that induce motility and degrade the extracellular matrix [134]. Furthermore, a 
major hallmark of EMT is a shift in cadherin expression, that is, suppression of 
epithelia cadherins such as CDH1/E-cadherin and induction of mesenchymal 
cadherins like N-cadherin and cadherin-11. Simplified, E-cadherin is important 
for cell-cell adherence, thus keeping the organization of cells in the tissue, while 
N-cadherin and cadherin 11 are important for cell movement by interactions 
with neighboring cells and the cytoskeleton [135, 136].  
 Hypoxia and hypoxia inducible factor 1 (HIF1) 1.4.2
A common feature of solid tumors is the decreased level of oxygen, hypoxia, in 
the tumor tissue [137]. Hypoxia has been shown to promote carcinogenesis and 
an aggressive cancer-cell phenotype [138, 139]. Furthermore, the low oxygen 
levels within the tumor, promote cancer-endorsing crosstalk between tumor 
cells and the surrounding stroma [8, 140, 141]. In line, hypoxia is an 
independent negative prognostic factor in solid tumors [142]. 
The major hypoxia associated transcription factor, hypoxia inducible factor 1 
(HIF1), consists of two subunits; the β-subunit and the hypoxia stabilized α-
subunit. Without stabilization, the HIF1α subunit is rapidly degraded and HIF1 
activity prohibited [143]. High expression of HIF1α in prostatic intraepithelial 
neoplasia (PIN), the precursor of PC, but low expression in benign prostatic 
hyperplasia (BPH), suggests that induction of HIF1α is an early event during PC 
development [144].  
In addition to stimulation by hypoxia, HIF1 activity can be induced by oncogenic 
signals, e.g. via interplay with the PI3K-Akt and IL6/STAT3 pathways [145-150]. 
Moreover, cells with potential to evade hypoxia induced apoptosis by induction 
of anti-apoptotic proteins such as B-cell lymphoma 2 (BCL-2) are enriched in the 
hypoxic tumour environment [151-153]. In turn, BCL-2 has been shown to 
stabilize HIF1α [154] and induce the transcription of vascular endothelial 
growth factor (VEGF) [155, 156], the primary target of HIF1. 
HIF1 regulates the transcription of numerous genes involved in the metastatic 
process, including TWIST, VEGFA, matrix metalloproteinases (MMPs) and IL-6 
(reviewed in [145]). However, although hypoxia has been shown to initiate 
epithelial-mesenchymal transition (EMT) by induction of transcription factors 
such as TWIST and snail, it is not necessarily a full EMT associated with 
increased tumor cell motility [157, 158].  
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Furthermore, HIF1 has been shown to contribute to castration-resistant tumor 
growth, in part by its ability to facilitate AR activation under androgen reduced 
conditions [159, 160] and further, by induction of metabolic alterations in an 
AR-independent manner [161]. 
 PI3K/AKT and IL-6/STAT3 pathways 1.4.3
The two pathways that are addressed in the work of this thesis (paper I) are the 
PI3K/AKT and IL-6/STAT3 pathways. The PI3K/AKT pathway is commonly up-
regulated in PC in association with cancer progression, metastasis and 
castration-resistant tumor growth [120, 122, 125, 126]. The pathway is initiated 
by the stimulation of a tyrosine kinase receptor (RTK) or G- protein coupled 
receptor (GPCR), the pathway includes several phosphorylation steps including 
the phosphorylation/activation of the effector RAC-alpha serine/threonine-
protein kinase (AKT) [162]. Following activation, AKT phosphorylates and 
regulate down-stream oncogenic signals directly e.g. (BAD, BAX, FOXO) [163, 
164] or indirectly (mTORC, via the inhibition of TSC2) [165, 166].  
The rate limiting step in the PI3K/AKT pathway, is the phosphorylation of 
phosphatidylinositol (4,5)-bisphosphate (PIP2), to (3,4,5)-trisphosphate (PIP3), 
which recruits AKT to the plasma membrane enabling its activation. The 
phosphorylation of PIP2 is catalyzed by phosphoinositide 3-kinase (PI3K) while 
the dephosphorylation is mediated by the tumor suppressor phosphatase 
tensin homolog (PTEN). Genomic alterations in the PI3K/AKT pathway is 
frequent in PC [126], e.g. PTEN which is often found silenced in primary PC and 
even more frequent in in metastatic PC [167-169], which results in a 
continuously active pathway.  
Furthermore, the AKT pathway and the AR pathway cross-communicate in a 
reciprocal compensatory manner, meaning loss of one enhances the other 
[120, 125, 170]. Additionally, AKT mediated phosphorylation has been shown to 
inhibit AR degradation [171]. The association between the AR and AKT 
pathways has evoked interest and the clinical benefit of combination 
treatments of AKT and AR targeting drugs are investigated in ongoing clinical 
trials.  
The IL-6/STAT3 pathway is initiated by stimulation of the interleukin-6 receptor, 
which activates Janus kinases (JAK). JAK subsequently phosphorylates/activates 
the signal transducer and activator of transcription 3 (STAT3) transcription 
factor [172]. Increased STAT3 activity has been reported in PC [122, 123] 
especially in bone metastases [121]. STAT3 activity has been shown to induce 
EMT in cancer [173, 174]. In, PC models, induction of EMT by increased STAT3 
signaling has been shown to promote stem-like properties [175, 176]. However, 
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down-regulation of STAT3 signaling in the PTEN deficient PC cell line LNCaP has 
been shown to induce the cells metastatic ability [119].  
 Prostate cancer bone metastases 1.5
The development of bone metastases is frequently occurring complication in PC 
and associated with poor prognosis as PC is incurable once it has settle in the 
bone. Additionally, bone metastases are associated with poor quality of life 
associated with skeletal-related events (pathologic fracture, spinal cord 
compression, necessity for radiation to bone (for pain or impending fracture) or 
surgery to bone) [177, 178].  
For the development of PC bone metastases, the first step is the dissociation of 
the tumor cell from the primary site. However, dissemination of primary PC 
cells is not enough for the development of PC metastases in bone. The 
metastatic process includes several additional steps including, invasion, 
intravasation, anti-anoikis, extravasation, homing and regrowth, each of these 
steps are rate limiting and critical; thus only a small fraction of the 
disseminating tumor cells (DTCs) actually forms distant tumors [179].  
For establishment in the bone, it has been proposed that the primary tumors 
prepare the target tissue for the DTC, by  secretion of factors, including 
parathyroid hormone-related protein (PTHrP), bone morphogenic proteins 
(BMPs) and VEGF that induces bone-turnover and angiogenesis [180, 181] 
Furthermore, PC tumor cells has been shown to adapt features of the residents 
of the bone (osteoblasts) – so called osteomimicry - in order to facilitate 
communication with the surrounding cells, and thus enhance their own survival 
[182]. This process is initiated during EMT, through the induction of the bone 
associated runt-related transcription factor 2 (RUNX2) [183, 184]. Furthermore, 
of the DTCs that reach the distant organ, a large fraction remains dormant and 
can reside at this stage for years [181, 185, 186]. Reawakening of dormant PC 
tumor cells has, for example been shown in association the suppression of the 
MAPK/ERK and PI3K/AKT pathways and subsequent induction of MET in 
response to factors produced by adjacent stroma cells [187, 188].  
PC bone tumors display mixed sclerotic-lytic properties with excessive bone 
formation, hence considered to have a sclerotic phenotype [189, 190]. The 
increased bone mass are the results of exaggerating activity of the osteoblasts, 
which are the bone forming cells. Osteoblasts arise from mesenchymal stem 
cells (MSCs) [191] that undergoes a strictly regulated  differentiation process to 
reach maturity and the ability to form the calcified matrix that constitute the 
bone. One of the regulators for this process is RUNX2, which regulates the 
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transcription of several genes associated with osteoblasts differentiation, 
directly or indirectly via its down-stream target, osterix [192, 193].  
Bone resorption is mediated by osteoclast. The osteoclasts are derived from 
hematopoietic progenitors, that are activated in response to the receptor 
activator of nuclear factor ҡβ ligand (RANKL), which initiate activation mediated 
by the progenitor expressed receptor, RANK [194]. The differentiation is 
inhibited by an osteoblast secreted factor, osteoprotegerin (OPG), which binds 
to RANKL hence preventing it from interaction with RANK. Normally, bone 
remodeling is a continuous process that is regulated both locally and 
systemically by factors such as parathyroid hormone (PTH), glucocorticoids, and 
estradiol. Under normal conditions the ratio between osteoblasts and 
osteoclasts, and their activity is strictly balanced. However, it is well known that 
cancer can corrupt the bone remodeling process, to favor the development of 
bone metastases shifting the balance to an either sclerotic or lytic tumor 
phenotype [195, 196].  
PC tumor cells in the bone, enters an autocatalytic cycle, by continuous 
production of osteoblast promoting factors including, PTHrP and BMPs which 
stimulate osteoblasts differentiation and activity and increase bone-turnover. 
Activated osteoblast respond by increased production of tumor promoting 
factors including transforming growth factor beta (TGFβ), IGF-1 and VEGF [197]. 
In addition, increased bone-turnover induces release of tumor stimulating 
factors such as TGFβ and IGF-1 that are incorporated in the bone matrix [181, 
193]. 
 Shifting the balance 1.5.1
RUNX2 is considered one of the major factors associated with the development 
of PC bone metastases. However, PC clinical studies have shown somewhat 
varied results regarding the prevalence of RUNX2 in primary tumors and bone 
metastases, as well as its clinical potential [198-200]. Experimental studies 
however, propose that RUNX expression is associated with aggressive an PC 
phenotype [201, 202]. RUNX2 has been shown to induce the expression of 
PTHrP and a lytic phenotype of breast cancer [203]. In line, induced RUNX2 
expression in osteoblasts has been shown to reduce the anabolic effects of PTH 
[204]. In bone, PTHrP and PTH signaling via, parathyroid hormone 1 receptor 
(PTHR1) in osteoblasts, has catabolic effects when administrated continuously 
[205, 206], while anabolic effects with intermitted administration [207-211]. 
The paracrine anabolic effect of PTH/ PTHrP has been shown in association with 
induced osteoblast differentiation, reduced apoptosis [208-210] and re-
activation of bone-lining cells [211]. The catabolic effects of prolonged 
endocrine stimulation, is associated with increases expression of RANKL, while 
suppressed expression of bone stimulating factors like OPG [205, 206]. The 
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RANKL/OPG balance has been studied in patients with breast, lung and prostate 
cancer bone metastases. For lung and breast cancers, which are associated with 
lytic bone metastases, both RANKL and OPG were increased, with an elevated 
RANKL/OPG ratio. However, for PC only OPG was increased, thus associated 
with a decreased RANKL/OPG ratio and subsequently a sclerotic phenotype 
[212].  
 Regulator of G-protein signaling 2 (RGS2) 1.6
RGS2 is located on 1q31 [213], it is a quite conserved gene with orthologs to 
the human RGS2 in about 200 species (NCBI). The gene is comprised of 5 exons 
and its promoter is associated with a CpG island (UCSC). The RGS2 protein is a 
small, rather uncomplicated protein. It harbors a highly preserved core-domain 
domain, which is characteristic for all RGS proteins, flanked by short amino and 
carboxyl terminal sequences. Four separate biological forms of RGS2 have been 
described, with supposedly distinct modes of action and cellular localization 
[214].  
The role for RGS2 in cancer is poorly understood. However, several distinct 
modes of actions have been described for RGS2, by which it can affect cells in 
both cancer promoting as well as suppressive ways. 
Aberrant RGS2 expression has been reported for several types of solid cancer 
including prostate cancer where RGS2 expression is generally decreased 
compared to normal or benign glandular tissue [215, 216]. In breast cancer 
there has been reports of both high [217] and low [218, 219] RGS2 levels 
compared to normal tissue. Considering the clinical relevance of RGS2 
expression, low RGS2 level has been shown as unfavorable prognostic marker 
for colon cancer [220] and breast cancer [221]. The association between low 
RGS2 and poor prognosis in breast cancer was supported by The human protein 
atlas (https://www.proteinatlas.org/ENSG00000116741-RGS2/pathology), 
which further suggests that high RGS2 is an unfavorable marker for renal and 
stomach cancer. Additionally, in lung adenocarcinoma, high RGS2 expression 
was associated with poor overall survival, and identified as an independent 
prognostic factor [222].  
RGS2, was initially identified as a putative lymphocyte G0/G1 switch gene, then 
annotated G0S8, isolated by its transient induction in response to cell cycle 
stimulation [223, 224]. During the same time, it was shown that RGS2 
expression was transiently elevated during G0/G1 cell cycle transition [224, 
225] and sequencing of RGS2/GS08 suggested shared similarities with genes 
involved in the cell cycle and in the immune system [225]. However, RGS2 was 
later renamed, after identification of the highly preserved core-domain 
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signifying of RGS proteins (the GAP domain) [226]. Since, RGS2 has mainly been 
considered for its inhibiting role of G-protein signaling.  
 Short about G-protein signaling and RGS proteins 1.6.1
G-protein coupled receptors (GPCRs) are important signal conveyers in all 
eukaryote organisms, there function are carried out by activation of the 
receptor and subsequent activation of G-proteins, which are categorized into 
four families (Gi/Go, Gs, Gq/G11 and G12/G13) annotated by the associated α-
subunit. G-proteins are in its inactive form composed of three subunits that 
upon activation (binding of GTP) dissociates and mediates signals both via the 
GTP-activated α-subunit and the free βγ-complex. Hydrolyze of the GTP stops 
the signal and initiates the reassembling of the subunits. Hydrolyze is enhanced 
by specific proteins regulator of G-protein signaling (RGS) proteins, which act 
like α-subunit specific GTPase activating proteins (GAPs) [5, 227]. This 
emphasizes the importance of RGS proteins. 
In addition, down-stream effects of G-protein signaling are depending on 
subtype of both the receptor and G-protein, as well as on regulatory proteins 
that conveys the signal between the receptor and the specific G-protein. 
Additionally, is the down-stream effect dependent on the present effector-
molecule [228]. Thus can one receptor mediate different signals and activate or 
inhibit distinct separate pathways depending on the cellular context.  
 RGS2, G-protein signaling and down-stream effects 1.6.2
Studies of RGS2 in regards of its ability to interfere with G-protein signaling 
have shown its ability to inhibit most Gα families in a context dependent 
manner. However, RGS2 has a strong preference for Gαq and low affinity for 
Gαi [229, 230]. Generalizing, Gq/11 and Gi signaling has opposing effects on 
AKT activation. Gi signaling have a stimulating effect whilst Gq/11 has an overall 
attenuating effect [227], the later mediated is via direct inhibitory interaction 
between Gαq and PI3K [231, 232]. However, this influence of Gq/11 signaling is 
not straightforward, suggesting that it depends on the cellular context 
(receptor and effector). Furthermore, there seem to be some consensus 
regarding the durance of Gq signaling, constitutive Gq/11 signaling has an 
overall inhibitory effects on AKT activation [232, 233], while temporary 
signaling has a stimulating effect [234, 235]. Additionally, differing observations 
has been made regarding RGS2 and its role in Gq/11 associated activation of 
AKT, while attenuating effects has been described [236], other studies show no 
inhibitory effect of RGS2 [235, 237]. However, RGS2 associated inhibition of the 
MAPK pathways have been associated via its attenuating effect on Gaq [235]. 
Additionally, although RGS2 does not act as a GAP for Gs, it can interact with Gs 
or the down-stream target adenylyl cyclase (AC) with subsequent decreased 
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cAMP accumulation [238-240], thus inhibiting the MAPK pathway and ERK 
phosphorylation [241].  
In osteoblasts, RGS2 has been shown to be important for desensitizing both 
Gq/11 and Gs signaling [242]; Thus, affecting central signals associated with 
bon-remodeling such as, Ca2+ oscillation and the accumulation of cAMP [243]. 
The expression of RGS2 has been shown to be transiently induced during 
osteogenic differentiation of human mesenchymal stem cells [244]. However, 
due to lack of an evident skeleton associated phenotype in rgs2-/- mice [245], it 
has been proposed that RGS2s effect on bone development under basal 
conditions is limited. The significance of RGS2 has been associated to its 
attenuating effect on PTH and PTHrP stimulation [246], which is mediated via 
the Gs and Gq signaling, type 1 PTH/PTHrP receptor (PTH1R) [247]. Temporary 
signaling via PTH1R by intermitted stimulation by PTH and PTHrP is essential for 
osteoblast differentiation, proliferation and survival [248-250]. In line with the 
PTH1R regulatory role for RGS2 in osteblasts, RGS2 is fast and transiently 
upregulated in in bone in respons to PTH, PTHrP and PGE2 stimulation. 
Furthermore, this induction was confined to bone although the study 
considered other PTH1R expressing tissues (brain, heart, kidney, liver and 
spleen) [251].  
 Other roles for RGS2 1.6.3
In addition, RGS2 has been shown to interact with other proteins by 
mechanisms distinct from its GAP activity. These interactions will be described 
here, in relation to its biological implications. 
The expression of RGS2 has been shown to increase rapidly in response to 
stress, such as heat shock [252] and oxidative stress induced by H2O2 [253]. In 
addition, RGS2 has ability to both suppress and global protein translation [254] 
and promote translation of stress related genes [255] by direct interaction with 
the eukaryotic initiation factor 2B (eIF2B). RGS2 has thus been proposed to be 
regulatory of cellular stress response. 
The expression of RGS2 is further regulated by hypoxia, in a cell type and/or 
context specific manner. In smooth muscle cells RGS2 expression was 
suppressed after 48h of hypoxic exposure [256], while induced in myeloid 
derived suppressor cells (MDSC) after 1h exposure, however also increases in 
tumor derived MDSC compared to control. The authors further showed that 
RGS2 had pro-angiogenic properties [257]. Moreover, in pancreatic β-cells RGS2 
expression has been shown to be protective from hypoxia induced apoptosis 
[258]. In line with this observation, in mouse embryonic fibroblasts RGS2 has 
been shown to facilitate HIF1 mediated transcription with positive effects on 
cell-lifespan, associated with decreased stress induced apoptosis and 
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senescence. In this context, RGS2 was shown to assist HIF1 mediated 
transcription by interactions with the HIF1α subunit and the DNA [259].  
Additionally, RGS2 has also been shown to suppress STAT3 regulated 
expression via direct interaction [260]. There are also reports of nuclear 
localization of RGS2 both under basal conditions and in response stimulation by 
stress [261, 262]. Taken together, this suggests a direct role for RGS2 in 
regulation of transcription. 
RGS2 has furthermore been shown to be involved in yet another distinct 
cellular context. In a neural cell model, the PC12 cell line, RGS2 has been shown 
to associate with α-tubulin and contribute to microtubule polymerization [263]. 
In mouse oocytes, inhibition of the interaction between RGS2 and β-tubulin 
disrupted the meiotic spindle and chromosomal separation [264]. In addition, in 
HeLa cells RGS2 knockdown resulted in improper mitotic spindle organization 
and orientation, and significant mitotic delay [265]. 
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Figure 4. Illustration of the described modes of actions for RGS2. 
(A) Attenuation of GPCR signaling by inhibition of the α-subunit, mainly via the RGS2 
GAP activity directed towards Gαq signaling. (B) Regulation of protein translation via 
interaction with eIF2B. (C) Regulation of transcription by co-regulatory role via 
interaction with transcription factors or DNA, e.g. assisting of HIF1 mediated 
transcription by binding with the HIF1α subunit and/or direct interaction with the DNA 
strand. (D) Positive effects on mitotic-spindle formation and cell division, by regulatory 
interaction during polymerization of microtubule. Integrated photo depictures a dividing 
LNCaP cell stained for RGS2. HRE, Hypoxia-response element; AUG, the protein 
translation initiation codon. Not depictured are the ribosomal protein translational 
complex and transcriptional complex. 
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2 AIMS 
The overall aim of this thesis was to analyze RGS2 expression in prostate 
cancer, with main emphasis on development of advanced disease. 
 
• To analyze the expression of RGS2 at different stages of 
prostate cancer in relation to cancer progression and tumor 
phenotype 
 
• To assess the regulation of RGS2 expression at the different 
stages of prostate cancer 
 
• To evaluate the clinical value of RGS2 as a prognostic 
biomarker for prostate cancer 
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3 MATERIAL AND METHODS 
In this thesis the expression of RGS2 has been evaluated in association to the 
development and progression of PC. The general expression of RGS2 in benign 
and malignant prostatic tissue and its clinical implication has been evaluated in 
archival specimens. The regulation of RGS2 expression and subsequent 
influence on tumor phenotype at different stages and conditions of PC has 
been assessed in vivo and in vitro. 
 Clinical Specimens 3.1
RGS2 expression has been evaluated in benign prostate hyperplasia (BPH), 
primary tumors of hormone-naïve PC (HNPC), castration-resistant PC (CRPC), 
and in bone metastases (mHNPC and mCRPC). 
Paraffin-embedded archival prostatic specimens from transurethral resection of 
the prostate (TURP) and needle biopsies were retrospectively collected. BPH 
and HNPC patients were a diagnosed based on findings in the TURP material, 
while CRPC patients received TURP as palliative treatment for symptoms 
associated with local progress. 
PC bone metastatic tissue has been surgically removed due to SRE associated 
patient discomfort. For all studies, the use of anonymized material has been 
approved by the local ethical committees – at the Sahlgrenska University 
hospital in Gothenburg (paper I, II, IV) and Central Hospital in Västerås (Paper 
III).  
(For specification of the use of clinical tissue for the culture of primary 
fibroblast, see Experimental in vitro systems)  
 Clinical specimens Paper I 3.1.1
RGS2 was assessed with histological staining of archival TURP material from 
BPH (n=25) and early low-risk HNPC (n=28) to evaluate early expressional 
differences between benign and malignant tissue. The HNPC specimens were 
classified as stage T1b tumors - that is, unapparent non-palpable tumors with 
histological tumor finding in more than 5% of the resected tissue. For 
clinicophatological characteristics see paper II, table 1, cohort II. 
The homogeneity of the T1b specimens, led to the inclusion of a second 
archival material retrieved by needle biopsy (n=45), for assessment of RGS2 
expression in correlation to PC progression and for evaluation of clinical 
potential. The patients had locally advanced PC with PSA >80 ng/ml or 
metastatic PC, thus received ADT treatment immediately following diagnosis.  
Clinicopathological characteristics: T stage T1c-T4. Distribution of M stage 
followed: M1=26 M0=12 and MX=7. In addition, one patient had distant lymph 
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node metastatic status N1, the remaining patients were NX. Gleason score 
ranged from 6-9, with a median score of 7. PSA value ranged from 12-2900 
ng/ml, with a median value of 208 ng/ml.  
Clinical value of RGS2 expression was evaluated alone or in association with 
known clinicopathological variables. The cause of death was determined by 
examination of clinical records. Patients included for cancer specific survival 
(CSS) and hazard analysis, n=43. Two patients were excluded due to insufficient 
or inadequate medical journal data. 
 Clinical specimens Paper II 3.1.2
For comparison of RGS2 expression in low-risk compared to advanced PC and 
for assessment of alterations associated with castration-resistance, TURP 
specimens from HNPC and locally advanced CRPC (n=22) was included. For 
clinicophatological characteristics, see Paper II, Table 1, Cohort I (CRPC) and 
Cohort II (HNPC).  
The CRPC patients were included based on local progress post treatment with 
GnRH analogues, total ablation therapy (TAB) or surgical castration. For 
evaluation of CSS all patients were included. 
For assessment of changes in RGS2 expression associated with castration, case 
matched primary tumor specimens were included. The samples were retrieved 
by needle biopsy before and after approximately 3 months of ADT (n=28). For 
clinicophatological characteristics, see Paper II, Table 1, Cohort III.  All patients 
were included for analysis of failure-free survival and hazard associated with 
RGS2 expression. 
 Clinical specimens Paper III 3.1.3
RGS2 was evaluated on tissue micro arrays, constructed from a large cohort of 
HNPC, retrieved by TURP and followed by watchful waiting until progress. For 
assessment of RGS2 staining in tumor epithelium, tumor stroma, normal 
epithelium, and normal stroma in relation to CCS the number of patients were 
182, 185, 178 and 193 respectively. The corresponding numbers for AR staining 
were 278, 275, 282 and 281. Further characterization is available in material 
and methods Paper III.  
 Clinical specimens Paper IV 3.1.4
RGS2 and RUNX2 protein expression was assessed in contemporary paraffin-
embedded material with immunohistochemistry for comparison between HNPC 
metastases (n=5) and CRPC metastases (n=13). RGS2 gene expression was 
furthermore evaluated in frozen, RNA later preserved, tissue from the same 
patients for correlation with AR, PSA and PTHLP.  
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 Experimental in vitro studies 3.2
Although experimental set-ups in in vitro do not recapitulate the heterogeneity 
of a tumor, the usage of a representative in vitro model is a time and cost 
efficient complement to in vivo studies to minimize the ethical issue regarding 
the usage of animal experiments. Thus, the cell cultures have been an 
important tool for controlled studies of RGS2 regulation and phenotypic 
alterations associated with changes in RGS2 expression.  
 Cell lines and culture 3.2.1
The experiments has been conducted with primarily commercial available cell 
lines, with addition of the in-house castration-resistant LNCaP derivate, LNCaP-
19 [266]. For experiments with immortalized cell lines, the passaging were kept 
to a minimum and no passages above 18 from the original passage were used 
for the work of this thesis. The cells were routinely tested for mycoplasma 
contamination. 
3.2.1.1 LNCaP-FGC (Lymph Node Carcinoma of the Prostate – Fast 
Growing Clone) 
(Paper I, Paper II and Paper IV) The main cell line used in the thesis has been 
LNCAP (ATCC® CRL-1740™). LNCaP has been used as the backbone for the 
studies of RGS2 in this thesis, based on its relatively high RGS2 expression. 
Furthermore, LNCAP grow readily both in vitro and in vivo (subcutaneously and 
orthotopicaly). 
The LNCaP cell line is a androgen-dependent/sensitive PC model derived from a 
lymph node metastasis [267]. LNCaP is one of the most common androgen-
sensitive cell lines used in PC research and under basal conditions it express the 
full length AR (AR-FL) [79]. It is generally considered androgen-dependent; 
however it harbors the AR T878A gain-of-function mutation which allows 
promiscuous response to additional ligands [93].  
3.2.1.2 LNCaP-19 
(Paper I, PaperII and Paper II). LNCaP-19 is a castration-resistant derivate of 
LNCaP that was established by prolonged passaging in hormone-depleted 
media [266]. LNCaP-19 expresses low levels of RGS2 under standard culture 
conditions. It expresses the AR, but insignificant levels of PSA under standard 
conditions. However, LNCaP-19 is androgen-responsive as hormonal 
stimulation of the AR induces PSA expression. LNCaP-19 grows well in vitro and 
in vivo (subcutaneously, orthotopically and intratibially), cell growth is however 
inhibited by hormone stimulation [266, 268]. 
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3.2.1.3 VCAP 
(Paper II). The androgen-responsive VCaP (ATCC® CRL-2876™), where included 
in the study of RGS2 expression in response to anti-androgen treatment with 
enzalutamide. VCaP is derived from a human vertebral bone metastasis from a 
CRPC patient. The cell line was passaged in mouse prior to culture 
establishment in vitro. VCaP express low levels of RGS2 under standard culture 
conditions ([269], supplementary data). 
3.2.1.4 22Rv1  
(Paper II) 22Rv1 (ATCC® CRL-2505™) is a castration-resistant derivate of the 
androgen-dependent CWR22R cell line which are derived from a primary 
prostate tumor [270]. The 22RV1 cell line was established by serial passaging in 
castrated mice prior to establishment in vitro [271]. 22RV1 express high levels 
of RGS2 compared to LNCaP under standard culture conditions ([269], 
supplementary data).  
3.2.1.5 WPMY-1  
(Paper 1) The cell line WPMY-1 (ATCC® CRL-2854™) was established from the 
stromal region of a primary prostate tumor. According to morphology it is 
characterized as a myofibroblast. In line, it expresses high levels of smooth 
muscle alpha-actin and vimentin [272].  
3.2.1.6 PC-3 
(Paper I). PC-3 (ECCC, Wiltshire, UK) is a cell line isolated from a human 
vertebral castratioin-resistant PC tumor [273]. PC-3 express insignificant levels 
of AR and is considered a true androgen-independent cell line [274]. PC-3 
express high levels of RGS2 in comparison to LNCaP ([269], supplementary 
data).   
3.2.1.7 Primary cell culture of fibroblasts 
(Paper III) The primary cultures of fibroblasts were established from radical 
prostatectomy or prostate adenoma enucleation tissue specimens, for PC 
associated or BPH associated fibroblasts respectively. No passages above 10 
were used. The use of patient material was approved by the local ethical 
committee in Homburg. All patients had given informed consent prior to 
inclusion in the study. 
3.2.1.8 Cell culturing standard conditions 
Cells were cultured at 37 °C in humidified air with 5% CO2 under atmospheric 
oxygen pressure unless stated differently. LNCaP, PC-3, 22Rv1 and LNCaP-19 
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were cultured in RPMI-1640 (PAA Laboratories) with stable glutamine, 
supplemented for a final concentration of 1 mM sodium pyruvate and 4500 
mg/l glucose. For complete growth media, fetal bovine serum (FBS; Gibco) was 
added to a final concentration of 10%, with the exception of LNCaP-19 where 
dextran-charcoal stripped FBS (DCC; Gibco) was used. WPMY-1 and VCaP was 
cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 5% and 
10% FBS respectively. Sh-clones were cultured according to protocol for LNCaP. 
All cells were cultured with antibiotics (Penicillin-Streptomycin; Thermo Fisher 
Scientific). Extra care was taken to keep the cultures subconfluent by repeated 
passaging.  
 Induction of hypoxia and stabilization of HIF1α in vitro 3.2.2
(Paper I) Experimental approach to evaluate the effect of reduced oxygen levels 
and HIF1α stabilization as a potential mechanism behind the down regulation 
of RGS2 documented in the clinical specimens of T1b PC tumors compared to 
BPH.  
The cells (LNCaP and LNCaP-19) were cultured under reduced oxygen levels (1% 
O2) in a hypoxia chamber (Sci-tive-N hypoxia workstation, Ruskinn Technology). 
Control cells were cultured under atmospheric oxygen in parallel. The 
experiment was terminated after 48 and 72 hours, when samples were 
collected. The hypoxia chamber was manually calibrated, and oxygen levels 
were verified frequently. For preparation of cell lysates, cells were kept on ice, 
rinsed with cold D-PBS (PAA Laboratories) and lysed directly in the culture flask 
to reduce HIF1α protein degradation. Complementary experiments with CoCl2 
(Sigma-Aldrich, St Louis, MO) were performed to validate the hypoxia data, 
with an additional set of cell lines (LNCaP, LNCaP-19, PC-3 and WPMY-1).  CoCl2 
treatment (150 μM) was carried out under normal atmospheric oxygen for 48 
or 72 hours. 
 Knockdown of RGS2 3.2.3
For assessment of the significance for RGS2 at different stages of PC, RGS2 was 
stably knocked-down in the LNCaP cell line, generating the ShRGS2 sub clone. 
The control clone (shNT) was compared to LNCaP in vitro and showed 
concomitant behavior and expression profile in direct comparison. Evaluation 
of in vivo behavior was made retrospectively, with comparable results 
considering tumor take, growth rate and phenotype.  
The procedure in short: SureSilencing RGS2 shRNA Plasmid and non-target 
control ShNT (a scrambled sequence without genomic match) was purchased 
(KH02231N, Qiagen). Plasmids were enriched in E-coli and purified using the 
Rneasy Plus Universal Mini Kit (Qiagen). Plasmids were delivered using 
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electroporation with Nucelofector 2b and the Nucleofector Kit R (Lonza). Post 
transfection, cells were selected based on antibiotic resistance (Neomycin) and 
single clones were picked for establishment as isolated sub-clones.  RGS2 
expression was verified in the separate sub-clones using qPCR. The ShRGS2 
clone with the lowest RGS2 expression and the ShNT clone with an RGS2 
expression similar to LNCaP were chosen for further studies. The sub-clones 
were not cultured under continuous antibiotic pressure, but repeatedly tested 
for constant RGS2 expression. For instance, stable knockdown of RGS2 was 
assessed prior to implantation in mice, and confirmed in recovered tumor 
tissue. 
 Assessment of RGS2 knockdown 3.2.4
The effects of RGS2 knockdown in PC cell line LNCaP were assessed to establish 
the impact of RGS2. In addition to functional analysis of RGS2, morphological 
alterations associated with RGS2 knockdown was evaluated using bright field 
microscopy and phase-contrast imaging. 
3.2.4.1 Growth curve 
(Paper I-II) Growth rate was determined under standard growth conditions and 
in the hormone-deprived setting. Cells were starved for 24 hours (h) and then 
counted. Media was replaced with standard culture media or hormone 
depleted media, following the next 72 h period the cells were counted 
sequentially with a 24 h interval. Cell count was performed using trypan blue 
and the Countess™ Automated Cell Counter (Invitrogen). 
3.2.4.2 Scratch assay 
(Paper I) To assess the effect on motility of RGS2 knockdown, a scratch assay 
was performed. Cells were plated on 6-well plates and allowed to grow until ≥ 
80% confluence. A scratch was made using a sterile pipette tip, culture medium 
was changed and position markings were made from the bottom to ensure 
consistency in gap evaluation. Sequential images were captures over the next 
72 h, with 24 h interval, using a Nikon TMS inverted microscope equipped with 
a Lumenera Infinity 1 camera. The gap area was measured using the Infinity 
software. Gap closure was calculated respective to the initial area. 
3.2.4.3 Clonogenic assay  
(Paper I) To test the ability of the clones to form single colonies, 10 000 cells 
were plated onto BioCoat™ Poly-D-Lysine coated 6-Well plates (Corning, NY) 
and cultured for 21 days. Media was carefully replaced every second or third 
day. Formed colonies was washed, fixed with 4% PFA and stained with crystal 
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violet (0.5% in 4% PFA). Single colonies of approximately ≥ 30 cells were 
counted using an inverted microscope. 
3.2.4.4 Cell cycle profile 
(Paper I) Cell cycle profile was assessed under standard conditions. Cells were 
detached from the culture dish and centrifuged with the collected original 
culture media. After wash in D-PBS, the pellet were subsequently resuspended 
in Vindelov’s reagent (75 μmol/L propidium iodide (PI), 20 mmol/L Tris, 100 
mmol/L NaCl, 0.1% Nonidet p-40, and 20 μg/ml RNase adjusted to pH 8.0) at a 
cell concentration of ≤ 106 cells per ml and incubated for 30 min at 37°C prior to 
analysis. PI staining was analyzed with BD Accuri C6 flow cytometer. For cell 
cycle profile, DNA content was analyzed using the FL3 channel on linear scale. 
Cells were considered apoptotic when showing less then diploid DNA content 
(sub-G1/-log 1) on logarithmic scale via the FL2 channel. 
 RGS2 expression in association to AR activity 3.2.5
(Paper II) RGS2 expression was assessed in association to AR activity in vitro to 
evaluate findings from the clinical specimens.  
3.2.5.1 Hormone starvation  
To study the effect of AR activity on RGS2 expression, LNCaP was subjected to 
hormone depletion, established by the exchange of FBS for DCC in standard 
culturing media (final concentration of 10%). For comparison, AR was 
stimulated in a parallel set-up by the addition of 1 or 10 nm DHT. Cells were 
cultured under these conditions for 35 days when RNA and protein was 
harvested for subsequent analysis. Equivalent amount of ethanol was used a 
vehicle control for the hormone starved group. The purpose of the experiment 
was to compare the expression of RGS2 between stimulated and non-
stimulated AR. Thus, phenol-free media was used to constitute for the LNCaP 
promiscuous promoter.  
3.2.5.2 AR inhibition by enzalutamide 
LNCaP, VCaP and 22Rv1 was subjected to enzalutamide treatment for 72 hours. 
Cells were starved for 24 h prior to change to standard growth media 
supplemented with 10 µM enzalutamide or equivalent amount of DMSO as 
vehicle control.   
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 Experimental In vivo studies 3.3
Animal models enable studies of mechanism associated with development and 
progression of cancer in contexts that reproduces the heterogeneity in the 
tumor environment. The animal models thus offer a complexity that cannot be 
achieved in the cell culture. In the present thesis male athymic BALB/c nude 
mice (Charles River Laboratories International) were used throughout. The mice 
were at least 8 weeks old at the time for experimental initiation to ensure 
sexual maturity. For better initiation of PC growth in vivo, MatrigelTM (BD 
Biosciences) – a protein rich matrix resembling product - was used. To certify 
that viable cells were used throughout the experiment, good cell viability was 
established with trypan blue prior to inoculation and for the remaining cells 
after all animals was operated. The use of animals was approved by the local 
ethical committee in Gothenburg.  
 Subcutaneous implantation 3.3.1
(Paper I) The advantage with subcutaneous inoculation is the possibility to 
easily follow the tumor growth with a calliper. Thus this was the primary choice 
for assessment of the effect of RGS2 knockdown on tumor development and 
growth. 
 A total of 10 mice were used in the experiment, 5 and 5 were inoculated with 
ShRGS2 or ShNT. Two million cells, resuspended in 200 μl of 1:1 antibiotic-free 
media and MatrigelTM, were injected on the left flank. Animals were sacrificed 
10 weeks post implantation or before, if the tumors had reached the ethically 
approved tumor volume of 1300 mm3. Animals were monitored weekly when 
also tumors were measured using a calliper. Tumor volume (V) was calculated 
using the formula V = (length × width2)/2. Tumor growth was normalized by 
calculation of volume relative to first detected tumor volume. Harvested 
tumors was weight and preserved with RNAlater® Solution(Ambion, Austin, TX) 
for future RNA/protein extraction or fixed in 4% paraformaldehyde for paraffin 
embedding. 
 Orthotopic implantation 3.3.2
(Paper I-II) Orthotopic implantations of PC cells were performed for analysis of 
RGS2 expression in a milieu that resembles the human prostate. Implantation 
in the dorsolateral lobe of the mouse prostate best mimics the clinical situation, 
regarding corresponding expression and cell composition compared to the 
human peripheral zone [275]. In this environment, the expression of RGS2 was 
studied in association with hypoxia and development of castration-resistant 
tumors. 
Orthotopic implantation was carried out via a T-incision in the lower abdomen. 
When applicable, castration was performed via the same incision*. 1 million PC 
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cells (LNCaP and LNCaP-19) in 7 μl of BD Matrigel were implanted using a 30 
gauge needle. For anesthetiza and analgesics a mixture of xylazine/ketamine 
(0.55 mg/kg; 110 mg/kg) were administrated prior to operation. The animals 
were there after kept sedated with isoflurane during surgery. Animals were 
sacrificed 10 weeks after implantation, or before if signs of tumor-induced 
discomfort were displayed. Harvested tumors tissue was weight and preserved 
with RNAlater® Solution for future RNA/protein extraction or fixed in 4% 
paraformaldehyde for paraffin embedding.  
*For assessment of castration-resistant tumor growth animals were castrated, 
developed tumors were compared to a non-castrated control group. RGS2 
expression in association to hypoxia was analyzed in non-castrated animals.  
 Intratibial implantation 3.3.3
(Paper IV) The effects of RGS2 knockdown on development and phenotype of 
bone metastases were evaluated by intratibial implantation of ShRGS2 (n=10) 
and ShNT (n=10) in castrated mice. The castration was performed mainly due to 
documented poor establishment of LNCaP in non-castrated animals [276], and 
by reason of the observed high expression of RGS2 in human CRPC bone 
metastatic specimens.  
One million cells in 7 µl BD MatrigelTM (BD Biosciences), was implanted with a 
29 G needle in the left tibia through the cortex of the anterior tuberosity using 
a drilling motion to avoid cortical fracture. Animals were castrated via a scrotal 
incision in association with the implantation. For analgesics, 5 mg/kg rimadyl 
was administrated 30 minutes prior to surgery and for 5 days post-surgery. 
During operation, the animals were sedated using isoflurane. The experiment 
was ended 10 weeks post implantation, when animals where sacrificed and 
tibia and blood was collected. Blood was stored as serum at -80°C for later 
assessment. Tibia was dissected and preserved in 4% paraformaldehyde for 
histological evaluation. The specimens were subsequently demineralized in 
modified formic acid and sectioned (4 µm) (Histolab, Sweden). Tumor 
establishment was evaluated by hematoxyline and eosin (H&E) staining of 
continuous sagittal sections. 
For control of castration effects, 6 male C57BL/6 mice were included. Three 
animals were castrated and three underwent sham operation. Animals were 
sacrificed after 1 week, when tibia was collected. Tibia specimens were treated 
in accordance with previous description. 
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 Assessment of gene expression 3.4
 RNA extraction and cDNA preparation 3.4.1
(Paper I, II, IV). Total-RNA from cultured cells or tumor tissues was isolated 
using the AllPrep DNA/RNA Mini Kit or RNeasy mini kit (Qiagen) according to 
provided protocol. For tumor tissue, RNA integrity number (RIN) was 
determined with the Agilent 2100 Bioanalyzer (Agilent Technologies). RNA 
samples with a RIN less than 6 were excluded. RNA concentrations and purity 
was evaluated photospectrometically with a NanoDrop™ (Thermo Fisher 
Scientific). cDNA was prepared by reverse transcription with SuperScript® 
VILO™ cDNA Synthesis Kit, according to provided protocol. 
(Paper III) Total-RNA was isolated from cell pellets with RNeasy Kits (Qiagen) 
and reverse transcribed to cDNA using Superscript III reverse transcriptase 
(Thermo Fisher) and Oligo-dT Primers (Qiagen). 
 Quantitative real-time polymerase chain reaction (qPCR) 3.4.2
(Paper I-IV) Real-time PCR was performed with ABI 7500 Fast sequence 
Detector (Applied Biosystems) or 96 well Step One Plus system (Thermo Fisher) 
with gene-specific TaqMan® Assays (Applied Biosystems). TaqMan® Assays that 
span exons were exclusively chosen to avoid detection of potentially 
contaminating genomic DNA. Expression of target genes was calculated with 
the 2-ΔΔCT method. Endogenous controls were chosen for its stable expression 
under the specific experimental condition. 
 Gene expression profile 3.4.3
For a gross overview of the effects of RGS2-knockdown the analysis of a 
GrandPerformance CTC Assay Panel (TATAA Biocenter) [277] was performed 
using the ValidPrimeTM assay kit (TATAA Biocenter). qPCR was performed on 
BioMark (Fluidigm) using the 96.96 Dynamic Array™ IFC (Integrated Fluidic 
Circuit). Reverse transcription and qPCR was performed at TATAA. Biocenter 
(Gothenburg, Sweden). Samples were analyzed in one replicate. 
 Assessment of protein expression 3.5
 Immunohistochemistry (IHC) 3.5.1
Immunohistochemistry (IHC) has been used as a methodology-backbone for the 
papers included in the thesis. IHC data from the human specimens has opened 
up for explorative experiments to describe the clinical observations. 
IHC was used for evaluation of protein expression of RGS2 in TURP and needle 
biopsy specimens as well as in animal tumor xenografts. In addition, IHC was 
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used to evaluate expression of RUNX2 and AR in PC bone metastases specimens 
and TMAs, respectively.  
In tumor xenografts, IHC was used to visualize hypoxic regions and blood 
vessels by staining for carbonic anhydrase 9 (CAIX) or HIF1A and CD31, 
respectively. Furthermore, proliferation was assessed by immunohistological 
evaluation of Ki67 expression.   
All IHC protocols included the following steps: Deparaffinization, rehydration in 
graded ethanol, antigen retrieval, inhibition of endogenous peroxidase and 
blocking of non-specific epitope binding, before incubation with primary 
antibody. IHC staining of tumor xenografts (all markers), TURP specimens 
(including TMA) and bone metastases was performed using the Vectastain Elite 
ABC kit (Vector Laboratories), with the exception of staining for AR where the 
Ventana ES platform (Ventana) was used. IHC staining of the needle biopsy 
material was performed with EnVision FLEX system (Dako). For visualization of 
HRP reaction 3,3'diaminobenzidine (DAB), was used (Liquid DAB+ Substrate 
Chromogen System, Dako) or (iView DAB Detection kit, Ventana), the later for 
AR staining (paper III). 
Primary antibodies used were anti-RGS2 (ab36561, AbCam), anti-CAIX 
(ab15086, Abcam) anti-HIF1A (ab51608, Abcam) anti-CD31 (77699, Cell 
signaling), anti-Ki67 (MA5-14520, Thermo Fisher Scientific), anti-RUNX2 
(ab23981, Abcam) and AR (MU256-UCE, BioGenex). 
3.5.1.1 Quantification of IHC staining in clinical specimens (scoring) 
For IHC scoring of clinical specimens, intensity and proportion (distribution) of 
the staining was considered for cancer cells, stromal cells and normal epithelial 
cells when valid.  
(Paper I, II and IV). The intensity of the epithelial staining of RGS2 was scored 
according to: 0 = no detectable staining, 1 = weak staining, 2 = moderate 
staining, and 3 = strong staining; the proportion of positive cells was scored as 0 
< 5%, 1 ≤ 33%, 2 ≤ 66%, and 3 > 66% positive cells. Proportion score was 
multiplied by the intensity value, and these values were totaled generating a 
RGS2 section score.  
(Paper I-II) Stromal staining was scored accordingly for stroma visible at 10X 
magnification with the cancer area in focus. The median of three separate 
hotspots rendered the stromal RGS2 section score. 
 (Paper III) The distribution was scored according to: “no stained cells” = 0, 
< 10% = 1, 10 - 50% = 2, 50 - 90% = 3 and > 90% = 4. Intensity of the dominant 
RGS2 staining per TMA was also performed and graded 1-4. The combined 
score is referred to as H – score in the paper. The main focus in paper III has 
been the distribution, thus are the H-score only been assessed in relation to 
expression of pAKT and GS.  
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(Paper IV) Epithelial expression of RUNX2 was scored as described above for 
RGS2 scoring in paper I and II. RGS2 expression in osteoblasts was scored 
similarly, based on number of osteoblasts with a specific intensity (0-3) out of 
the total number at a specific locus. Osteoblasts at 3-5 loci per tumor specimen 
were calculated. 
3.5.1.2 Quantification of IHC in in vivo material 
(Paper I) For quantification of proliferation, Ki67 positive cells were counted at 
20 times (20X) magnification for two hotspots per tumor. Staining was classified 
according to: positive = strong staining, negative = no staining and ambiguous = 
weak staining. Cell count data was obtained manually with the ImageJ 
software.  
(Paper IV) Scoring of RGS2 expression in osteoblasts was performed according 
to above description for scoring in human patient material. 
 Immunocytochemistry (ICC) 3.5.2
For evaluation of E-cadherin expression in ShRGS2 and ShNT, cells were 
cultured on 8-well glass slide culture chambers until 70% confluence. The slides 
were subsequently carefully washed and fixed with 4% neutral phosphate 
buffered formalin (4% PFA) on ice for 45 min, washed and stored in PBS at 4°C 
until staining (normally within two days). Anti-E-cadherin (610182; BD 
Transduction laboratories) was detected with Alexa FluorTM Plus 555 goat anti-
mouse IgG (H+L) secondary antibody (A32727; Thermo Fisher Scientific). Slides 
were mounted with ProLong™ Diamond Antifade Mountant with DAPI (Thermo 
Fisher Scientific).  
 Western blot (WB) 3.5.3
(Paper I-II) Western blot has been used to evaluate if transcriptional alterations 
are translated to protein level, to assess AKT activation and HIF1α stabilization.  
Protein samples were prepared from directly lysed or pelleted cells using  
CelLytic M™ lysis buffer (Sigma Aldrich) and tumor tissue was lysed using RIPA 
buffer with 1% IGEPAL® (Sigma Aldrich). Lysis buffers were supplemented with 
protease and phosphate inhibitors (cOmplete mini, PhosSTOP (Roche 
Diagnostics)). Following sonication and centrifugation the protein 
concentration was determined using BCA Protein assay kit (Pierce Chemicals).  
Protein samples (20-35 µg total protein) were separated according size under 
reducing conditions. The Invitrogen NuPAGE 4-12% Bis-Tris gradient gel 
(Thermo Fisher Scientific) has been used together with MOPS running buffer 
(Thermo Fisher Scientific) for best separation of proteins of interest. Transfer to 
polyvinylidene difluoride (PVDF) membranes has been performed using the 
i-Blot dry blot transfer system (Thermo Fisher Scientific). After transfer, the 
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membranes were blocked in 5% BSA, (Albumin from bovine serum; Sigma-
Aldrich) or 2% Amersham™ ECL Prime Blocking Agent (GE Healthcare), the later 
also used as primary antibody diluent, before incubation with primary antibody. 
Binding of HRP conjugated secondary antibody was detected using the 
Amersham™ ECL select Western Blotting Detection Reagent (GE Healthcare) 
and the peroxidase reaction was visualized using the LAS1000 image- detection 
system (Fujifilm Life Science). 
The following antibodies were used: anti-RGS2 (H00005997-M0; Abnova), anti-
RGS2 (ab36561; AbCam), anti-TWIST (Sc-81417, Santa Cruz Biotechnology), 
anti-BCl-2 (ms-123-p1; NeoMarker, Fremont, CA), anti-E-Cadherin, (610182; BD 
Transduction laboratories), anti-Pan-AKT (4691; Cell signaling), anti-p-AKT 
(4058; Cell signaling), anti-STAT3 (12640; Cell signaling), anti-PSA (RB-9056-P; 
NeoMarkers) and anti-HIF1Α (ab51608; AbCam). For control of adequate 
loading, anti-β actin (A5441; Sigma-Aldrich) has been used throughout. 
 Enzyme-linked immunosorbent assay (ELISA) 3.5.4
(Paper IV) Serum levels of PTHrP in animals after intratibial implantation of PC 
cells and tumor negative controls, was analyzed with sandwich ELISA specific 
for the 1-34 N-terminal region of human PTHrP (E-EL-H1478, Elabscience 
Biotechnology Co., Ltd.) according to protocol supplied by the manufacturer. 
The specificity for human PTHrP certified cancer cell-specific expression. 
Base-line PTHrP expression in the cell lines were assessed with the same 
technique and evaluated in whole cell lysates (20 µg total protein). 
 Statistics 3.6
Statistical analyses were carried out using IBM SPSS Statistics, version 24. For all 
tests *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 were considered significant.  
For comparisons of IHC scores, the Mann-Whitney U test was used to identify 
differences between groups, and Wilcoxon W paired test was used for analysis 
of intra-sectional differences or between TMA specimens from the same 
patient. For analysis of survival and FFS, Kaplan-Meier charts was created, Chi-
square and Log-rank (Mantel-Cox) was used to define statistical differences. For 
Kaplan-Meier charts, the score was dichotomized according to median score or 
grouped as described. For Cox regression analysis the 95% confidence interval 
(CI) is specified. A log10 transformation was applied for variables with a 
significantly skewed distribution (p-value < 0.01 with Shapiro-Wilk test of 
normality). When the condition for normality was still not met the median was 
used as cutoff. Potential interaction between each variable and time was 
evaluated. Proportion hazard assumption (PH) was not violated for any of the 
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variables. Student’s t-test was used to calculate statistical significance for 
differences between groups in gene expression, phenotypic properties and for 
osteoblast counts. The Spearman rank correlation was used throughout for 
evaluation of correlation of variables of interest. 
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4 RESULTS AND COMMENTS 
 (Paper I) Analysis of regulator of G-protein signalling 2 (RGS2) 4.1
expression and function during prostate cancer progression  
The significance of RGS2 in cancer has not been explored to any greater extent, 
and prognostic properties have showed varied results depending on the type of 
cancer investigated [220-222]. Thus, the present study was designed to 
evaluate RGS2 expression in PC tumors and to explore its clinical value. 
Additionally, RGS2 regulation and impact on tumor cell phenotype were 
assessed experimentally to interpret data from clinical materials. 
RGS2 was initially immunohistochemically assessed in clinical specimens of BPH 
(n=25) and low risk T1b PC specimens (n=28), which in some cases also included 
normal glandular tissue (n=8). In agreement with a previous publication [215], 
our data confirmed that RGS2 protein levels were considerably lower in PC 
compared to benign or normal glandular tissue. This was also noticeable for the 
surrounding stroma. However, when scrutinizing the data clozely - some 
diversity was observed regarding the level of RGS2 expression in the PC 
specimens.  
To assess the regulation of RGS2 expression and find a mechanism behind the 
heterogeneity observed in the PC specimens, RGS2 expression was 
immunohistochemically evaluated in orthotopic LNCaP PC xenografts in 
correlation to blood vessels, proliferation and hypoxia. The results showed that 
RGS2 expression was increased in well vascularized and proliferative areas in 
proximity to blood vessels. However, high levels of RGS2 were also identified in 
exceedingly hypoxic areas with extremely high HIF1α expression. Considering 
the general hypoxic environment in tumors and induction of HIF1α during 
development of malignancy [144], these findings were further evaluated in 
vitro. The data showed that time-limited exposure to hypoxia suppressed RGS2 
expression in the prostate cancer cell lines LNCaP and LNCaP-19. 
Complementary experiments with stabilization of HIF1α showed corresponding 
results, with decreased RSG2 expression in an extended cell line panel, 
including an additional PC cell line (PC-3) and a myofibroblast cell line (WPMY-
1). Taken together these data suggests that RGS2 is differently regulated by 
HIF1 in PC tumors, depending on the level and endurance of hypoxia. 
The homogeneity of the low risk PC cohort in terms of clinicopathological 
factors, did not allow for further evaluation but suggested inclusion of a second 
cohort with a more complex  composition for assessment of RGS2 expression in 
association with advanced PC (n=45). RGS2 expression did not significantly 
correlate with any of the clinicophatological variables available (PSA, GS, T-
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stage or age).  However, the data showed a strong trend for association 
between high RGS2 expression and positive metastatic status.  
Moreover, high RGS2 expression was significantly associated with poor cancer-
specific survival (CSS), with a mean survival of approximately 54 months 
compared to 102 months in the high and low expressing group respectively. 
The prognostic properties of RGS2 expression were further evaluated, showing 
that RGS2 and M-stage were the only prognostic factors for the present cohort. 
Additionally, when analyzed together with PSA, RSG2 was identified as an 
independent prognostic factor that outperformed PSA. Interestingly, 
unadjusted RGS2 showed better prognostic value than factors used for 
diagnosis in the clinic today (PSA, GS, T-stage). This identifies the clinical value 
of RGS2 expression for identification of high risk tumors. 
To evaluate the impact of the RGS2 expressional differences in PC tumor 
specimens, RGS2 was stably knocked-down in the LNCaP PC cell line. 
Phenotypic alterations were evaluated in comparison to the RGS2 expressing 
control clone. The data showed that knockdown of RGS2 had a significant 
negative effect on tumor cell motility and ability to form colonies. Furthermore, 
the knockdown of RGS2 altered cell morphology towards a more epithelial-like 
cell phenotype; displayed by a more organized growth pattern, increased 
polygonal shape and consistent dimensions. Additionally, uni-frontal movement 
and observed decreased preference for three-dimensional growth suggested 
that the knockdown of RGS2 had a positive effect on cell polarity. These 
phenotypical differences were in accordance with a less metastatic tumor cell 
phenotype.  
Additional assessment of the impact of RGS2 knockdown showed that 
decreased RGS2 expression was associated with reduced proliferation under 
standard culture conditions in vitro and under hypoxic pressure in 
subcutaneous tumor xenografts. This suggests that the high RGS2 expression 
documented in proliferative areas in orthotopic xenografts was not only 
associated but causative. Furthermore, cell cycle analysis suggested that under 
standard culture conditions in vitro, the cell population with RGS2 knockdown 
was less apoptotic, this was accompanied with an increased expression of BCL-2 
which was also confirmed in the subcutaneous xenografts.  
To evaluate the effects on tumor cell phenotype, proliferation and survival, the 
effect of RGS2 knockdown on pathways associated with PC development and 
progression was further evaluated. The data showed that while the activation 
of AKT was reduced by RSG2 knockdown, STAT3 protein expression was 
increased. Somewhat surprising, further evaluation suggested that, the 
knockdown of RGS2 induced an overall EMT-like expression profile, 
complemented by induced TWIST1, and reduced E-cadherin expression. 
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However, ICC evaluation of localization of E-cadherin expression did not show 
any obvious alterations comparing cells with RGS2 knockdown and RGS2 
expressing cells. 
In conclusion, these results suggest that RGS2 is generally suppressed by 
hypoxia in early low risk PC tumors, while induced by the increasingly hypoxic 
pressure in more advanced PC. Furthermore, RGS2 levels contribute to the PC 
tumor cell phenotype. Low RGS2 expression is associated with an indolent 
cancer phenotype representative of a major fraction of primary PC. In contrast, 
high RGS2 is associated with the proliferative metastatic phenotype that 
signifies progressed cancer. The data furthermore suggests that RGS2 
expression has a prognostic value and the potential to distinguishing between 
low- and high-risk patients.  
Finally, these results suggest that low RGS2 expression is associated with 
initiation of EMT by induction of STAT3 and TWIST1, while high RGS2 
expression is associated with activation of AKT. This distinction could rationalize 
for the described phenotypic alterations, and suggest that RGS2 expression 
could be indicative of therapeutic opportunities for treatments targeting the 
STAT3 and PI3K/AKT signaling pathways. 
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 (Paper II) RGS2 is prognostic for development of castration-4.2
resistance and cancer-specific survival in CRPC 
The interest for RGS2 in our group was evoked by distinct expression in LNCaP-
19 derived xenografts in response to growth site and availability of hormones, 
where RGS2 was up-regulated in orthotopic tumors compared to 
subcutaneous, and in intact compared to castrated animals [268]. Furthermore, 
a previous publication described the ability of RGS2 to inhibit androgen-
independent activation of the AR in the absence of androgens, postulating a 
mechanism by which decreased levels of RGS2 would promote castration-
resistant growth [269]. To assess these previous observations, the present 
study was designed to evaluate the expression of RGS2 in CRPC and in response 
to ADT and furthermore, assess the regulation of RGS2 experimentally in 
association to development of castration-resistant tumor growth.  
Evaluation of RGS2 expression by IHC showed that RGS2 protein expression was 
significantly higher in CRPC (n=22) compared to HNPC (n=28). To verify this 
finding, RGS2 expression was assessed in an additional data set retrieved from 
the Oncomine data base (HNPC, n=10; CRPC, n=25), with concordant results.  
Further evaluation of the data from the in-house patient material, showed that 
high RGS2 expression in the CRPC tumors was associated with significantly 
reduced CSS, with a mean survival of approximately 12 months compared to 24 
months in the high and low expressing group respectively. For stringency, a 
comparison was made exclusively with patients that harbored highly 
dedifferentiated tumors, signified by morphology similar to GG 5. With this 
inclusion, the difference in CSS were even more pronounced with median 
survival of 8 months compared to 25 months in the high and low RGS2 
expressing groups respectively.  The prognostic value of RGS2 expression was 
further evaluated. Data showed that, in agreement with the association 
between high RGS2 expression and poor survival, RGS2 was confirmed as an 
independent prognostic factor in CRPC. 
In addition, to assess the expression of RGS2 in association to ADT and 
acquisition of castration-resistance, RGS2 was immunohistocehmically 
evaluated in case matched advanced PC specimens before and after 3 months 
of ADT (n=28). The data showed that high levels of RGS2 expression post ADT 
was prognostic for decreased failure-free survival (FFS). Furthermore, when 
analyzed together with PSA, RGS2 was identified as an independent prognostic 
factor for FFS. The prognostic value for FFS was exclusive for RGS2 expression 
post ADT, RGS2 score before ADT was unassociated to FFS. Taken together, 
these data suggest that RGS2 expression could be valuable for interception of 
patients in need of additional treatment, at an early stage during initiation of 
ADT. 
Anna Linder 
39 
 
Further scrutinizing of the IHC score data showed that although RGS2 
expression in tumor specimens before and after ADT showed similar median 
expression, the major proportion of specimens showed an increased RGS2 
score after ADT (50%), while 21% showed an unchanged score and 29% a lower 
score. For evaluation of the response to ADT in respect of variation in RGS2 
expression, patients were grouped according to the change in RGS2 expression. 
The result showed that RGS2-response was prognostic for FFS. For patients 
with increased or constant high RGS2 expression, the median time between 
initiated ADT and relapse were 11 months compared to 25 months in the group 
were RGS2 was decreased.  
Additionally, since association between high RGS2 expression and metastasis 
was previously been shown in an extended form of the hormone-naive 
specimens (Paper I), this association was assessed in the post ADT specimens. 
The results showed that there was no correlation between RGS2 score post 
treatment and metastatic status, or between RGS2 score before and after ADT. 
Taken together, this suggests that regulation of RGS2 in response to ADT was 
associated with a distinct mechanism separate from metastatic progression.  
To further assess the high RGS2 levels associated with CRPC, RGS2 expression 
was evaluated in association to development of castration-resistance in 
orthotopic LNCaP xenografts. In this model LNCaP represent a hormone-naïve 
tumor cell that adapt to ADT. In agreement with the patient data, RGS2 levels 
where higher in tumors that had developed castration-resistance compared to 
tumors from non-castrated hosts. Furthermore, indicative of a castration-
resistance mechanism, elevated levels of AR expression and persistent AR 
activity, annotated by sustained PSA expression, was shown in the castration-
resistant tumors.  
A possible association between RGS2 level, AR level and AR activity was 
assessed in the Oncomine data set. Data showed a significant positive 
correlation between RGS2, AR and PSA in the CRPC group. Suggesting that the 
high levels of RGS2 expression in CRPC was associated with up-regulation of AR 
and sustained AR activity.  
In addition, the association between RGS2 and AR was assessed in association 
with hormone stimulation of castration-resistant tumors. This was considered 
with an additional orthotopic xenograft mouse model, using the castration-
resistant LNCaP-19. In contrast to LNCaP, LNCaP-19 has already acquired 
castration-resistance by a mechanism unassociated to induction of AR, 
suggested by low basal expression of both AR and PSA. The data showed that 
although the AR was significantly down-regulated in LNCap-19 derived tumors 
in response to hormone stimulation, significantly elevated levels of PSA 
indicated high AR activity. Notably, like PSA, RGS2 was significantly increased in 
tumors that developed in non-castrated animals compared to tumors from 
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castrated animals. This suggests that RGS2 expression was increased in 
response to AR stimulation.  
The association between AR activity and RGS2 expression was further assessed 
in vitro by enzalutamide treatment of androgen-responsive cell lines with 
different AR aberrations. During the current experimental conditions the three 
cell lines showed different expression profiles in response to enzalutamide 
treatment. LNCaP exhibited substantially decreased PSA expression, indicative 
of adequate AR inhibition, albeit induced AR expression. RGS2 expression was 
significantly down regulated, in line with an AR regulated expression of RGS2. 
The response for the androgen-independent cell line, 22RRv1 was not as 
distinct, a minor decrease in PSA expression suggested insufficient inhibition of 
AR activity. In line, RGS2 expression showed a minor reduction in the treated 
group compared to the control. Interestingly, the PSA expression for VCaP cells 
showed no reduction of AR activity in the treated group, denoted by equivalent 
levels of PSA, and notably expression of AR and RGS2 was increased in the 
treated group compared to the control. Importantly, during standard culture 
conditions, 22Rv1 exhibit high levels of RGS2, while VCaP express low levels 
compared to LNCaP. Combined, this suggests mechanisms behind the altered 
expression of RGS2 in response to ADT documented in the clinical specimens. 
Furthermore, in light of increased RGS2 expression in association to fast relapse 
after initiated ADT, this suggest that RGS2 expression could be reflective of 
resistance-mechanisms at an early stage during anti-androgen treatments. 
 
Wolff et al. previously suggested that RGS2 was decreased in LNCAP during 
hormone starvation, in association with acquisition of castration resistance 
[269]. In the present study, this was assessed in vitro by prolonged hormone-
starvation of LNCaP and comparison between the expression of RGS2 in LNCaP 
and LNCaP-19. In agreement with the previous study, RGS2 was significantly 
down-regulated in LNCaP cultured under hormone-depleted conditions. 
Furthermore, the down-regulation of RGS2 expression corresponded with 
reduced AR expression and activity. These alterations were emphasized in 
LNCaP-19.  Considering the heterogeneity of PC, this may represent a 
mechanism by which androgen responsive PC cells overcome ADT in the 
absence of hormone stimulation. However, considering data from the patient 
material, low levels of RGS2 in CRPC are infrequent and RGS2 expression is 
commonly induced during ADT. Aditionally, development of castration-resistant 
LNCaP tumors in vivo displayed increased levels of RGS2, and relatively low 
levels of DHT was sufficient to sustain RGS2 expression in vitro. Taken together, 
this emphasizes the ability of RGS2 to indicate persistent AR activity. 
Moreover, although LNCaP-19 grows readily under hormone-depleted 
conditions, hormone-starved LNCaP show significant reduced growth rate. The 
Anna Linder 
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contribution of RGS2 was assessed by the culture of cells with RGS2 knockdown 
and RGS2 expressing control in the absence of presence of androgens. The data 
showed that cells with RGS2 knockdown displayed significantly reduced cell 
growth compared to the control in the hormone deprived setting, while 
overlapping growth curves in hormone supplemented media. This indicates 
that although RGS2 is down-regulated by androgen deprivation, it is still 
important for proliferation in the primary androgen deprived setting. Thus, 
suggesting that high RGS2 expressing cells have an advantage under hormone 
depleted conditions. This is in line with decreased FFS for patients with high 
levels of RGS2 after initiated ADT.  
 
 In conclusion, the present study suggests that increased RGS2 expression in 
association to ADT and development of CRPC are both prevalent and associated 
with an aggressive cancer phenotype. Furthermore, RGS2 expression is 
indicative of continuous AR signaling, and may identify PC patients that would 
benefit from additional treatment at an early stage. 
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 (Paper III) Prognostic value of stromal expression of regulator 4.3
of G-protein signaling 2 (RGS2) and androgen receptor (AR) 
for men with prostate cancer followed with expectancy 
management  
In contrast to the previous studies included in this thesis, were the clinical value 
of RGS2 expression was evaluated in advanced forms of PC, the present patient 
material comprised of patients that were followed by expectancy management 
until signs of progress. This enables the evaluation of RGS2 expression and its 
clinical potential in a new setting. Furthermore, we have previously reported 
that RGS2 levels are significantly reduced in tumor associated stroma compared 
to stroma of benign tissue (Paper I), and in paper II we report that RGS2 
expression is decreased in stroma of advanced CRPC compared to low grade 
T1b specimens. Thus, the present study was designed to assess these 
observations and its clinical value. The association between AR and RGS2 was 
further assessed.  
The main aim of the present study has been to evaluate stromal expression of 
RGS2 and AR, with focus on cancer associated fibroblasts (CAFs) or non-CAFS 
(NCAFs) for fibroblasts adjacent normal tissue. 
For evaluation of previous findings (paper I), the H-score (combined variable of 
intensity and distribution) has been used in contrast to the distribution score, 
referred to as IR-score (immunoreactivity score), which was the general score 
used in the present study.  
The data showed that in agreement with previous observations, both stromal 
and epithelial RGS2 IR-score was decreased in PC specimens compared to 
normal tissue. This was also shown for AR IR-score. 
Tumor cell associated RGS2-IR score was significantly increased with higher T-
stage (T 1-2 vs T 3-4), but showed no significant difference considering other 
clinicopathological factors available (GS and M-stage).  
Stromal RGS2-IR score showed significant decrease in association with 
increased GS (G < 7 vs GS 7 - 10), but now significant difference considering 
other clinicopahtological factors. While low stromal AR-IR score was 
significantly associated with a positive metastatic status, high GS and T-stage.  
RGS2 and AR IR-score showed week but significant correlation in all cell types 
(CAFS, NCAFS, tumor cells and normal epithelium). Furthermore, stromal IR-
score for both markers showed week but significant correlation with Ki67 index 
score. Taken together, this suggests that low stromal expression of both 
markers was associated with more advanced PC. 
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The expression of RGS2 and AR was further assessed in vitro, in primary 
cultures of CAFs, NCAFs and BPH derived fibroblast (BPHFs). In agreement with 
the IHC score data, both markers showed general decreased expression in CAFs 
compared to both NCAFs and BPHFs.  
However, comparison of the expression of RGS2 in fibroblasts from the same 
prostatectomy showed that RGS2 expression was significantly decreased in 
CAFs compared to NCAFS, while the same comparison showed a trend for 
increased expression of AR. This suggests that, the expression of AR and RGS2 
in tumor stroma is not necessarily linked, which could rationalize the low 
correlation coefficients in the patient material. 
For evaluation of epithelial RGS2 expression in correlation to previously 
assessed clinical variables (paper I) and for evaluation of correlation to pAKT, 
the H-score was used. The data showed positive correlation between RGS2 
expression and pAKT. This data was in agreement with our previous 
observation of decreased AKT activation in response to RGS2 knockdown. 
Taken together, this suggests that RSG2 is an important regulatory factor for 
the PI3K/AKT pathway in PC.  
Additionally, in contrast to previous findings (paper I), RGS2 H-score showed 
significant correlation to GS (dichotomize GS < 8 vs GS 8 - 10). However, there 
was no significant correlation between RGS2 expression and M-stage, although 
the mean rank suggested higher expression in M1 compared to M0 patients.  
Moreover, both low RGS2-IR and AR- IR-score in CAFs (less than approximately 
30% positive cells) was correlated with significant reduced CSS. Loss of either 
RGS2 or AR was associated with poor survival compared to patients with 
sustained expression of both markers.  
The association between low stromal IR score for either marker and poor 
prognosis was confirmed with cox regression analysis. However, with inclusion 
of Ki67 proliferation index and pAKT, only AR-IR and Ki67 were significantly 
prognostic for CSS.  By further inclusion of GS and T-stage, only Ki-67 and GS 
were significantly prognostic for CSS. 
Taken together, this suggests that although both stromal RGS2 and AR 
expression has prognostic properties for CSS survival in PC, they are not adding 
further prognostic value compared with strong prognostic markers such as Ki67 
and GS in the current cohort.  
 
In conclusion, the present study suggests that low stromal expression of both 
AR and RGS2 is associated with more aggressive PC and has prognostic 
properties for identification of high-risk patients. In addition, epithelial RGS2 is 
indicative of an activated PI3K/AKT pathway. 
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 (Paper IV) Importance of RGS2 in prostate cancer bone 4.4
metastases 
The present study was design in light of the high levels of RGS2 in advanced PC 
and the suggested importance of RGS2 during normal bone development. 
Combined, this suggested that RGS2 could contribute to the sclerotic 
phenotype of PC bone metastases. Thus, was this ongoing study was designed 
to evaluate the expression of RGS2 in PC bone metastases (mPC), in general 
and in association with castration-resistant growth and furthermore, assess the 
significance of PC cell associated RGS2 expression during development of PC 
bone metastases and impact on tumor phenotype.  
Using IHC, RGS2 was initially assessed in a patient material including hormone-
naïve PC bone metastases (mHNPC, n=5) and castration-resistant PC bone 
metastases (mCRPC, n=13). The data showed that the general protein 
expression of RGS2 was high in the metastases. Additionally, RGS2 was 
increased in mCRPC compared to mHNPC.  
Morphological evaluation of the tumor specimens showed that mHNPC 
displayed glandular-like structures, suggestive of sustained cell polarity. This 
observation was exclusive for mHNPC. This suggests that the mCRPC tumors in 
generally was more dedifferentiated than the mHNPC tumors. 
Differential gene expression was thereafter assessed comparing the two tumor 
types considering gene expression for RGS2, AR and KLK3 (PSA). The data 
showed that RGS2 and AR expression was significantly up-regulated in mCRPC 
compared to mHNPC, while PSA displayed a statistically non-significant 
reversed expression. Moreover, evaluation of correlation between the different 
markers suggested that RGS2 expression was positively correlated with AR, 
while negatively correlated with PSA. PSA was also negatively correlated with 
AR. In light of previously described association between low levels of tissue 
PSA, despite increased nuclear staining of AR, and exceptionally aggressive PC 
bone metastases [278], these data suggest that high RGS2 expression is 
associated with a dedifferentiated aggressive mPC tumor phenotype.  
Furthermore, assessment of gene expression of PTHLH (PTHrP) showed that 
PTHLH was increased in mCRPC compared to mHNPC. Correlation analysis 
showed a trend for correlation between RGS2 and PTHLH, while PTHLH showed 
negative correlation with PSA. It has experimentally been shown that PTHrP is 
down-regulated in AR-positive PC cells in a DHT-dependent manner [279]. 
Furthermore, PSA exhibit enzymatic ability to cleave PTHrP into an inactive 
form [280, 281]. Taken together with induced RGS2 expression in PTHrP 
stimulated osteoblasts [208, 251], these data suggest a mechanism behind the 
up-regulation of RGS2 seen in epithelial cells of mCRPC.  
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The impact of RGS2 tumor epithelial expression in bone metastases was 
assessed with intratibial inoculation of LNCaP cells with stable knockdown 
(ShRGS2) and its non-target control (ShNT). The results showed that tumor cells 
with RGS2 knockdown displayed hampered ability to develop tumors in the 
bone compared to the RGS2 expressing control, with tumor take in 4 out of 10 
and 7 out of 9 operated animals, respectively. 
Established tumors from both groups reduced the castration-associated loss of 
trabecular bone and displayed a mixed blastic-lytic phenotype. However, RGS2 
expressing tumors showed augmented ability to form bone compared to 
tumors with RGS2 knockdown. This was associated with a significantly 
increased number of osteoblasts in the tumor-bone interface. The increased 
number of osteoblasts was local, in close association to the PC cells, suggesting 
that the stimulating factor is associated with paracrine cell-cell communication. 
Furthermore, for ShRGS2 derived tumors, 2 of the total 4 tumors displayed an 
evidently lytic phenotype - where the tumors grew outside the cortical bone - 
while none of the control tumors displayed extra-cortical growth. In agreement, 
the area of cortical bone in ShRGS2 tumors was reduced, compared to both 
control tumor-bearing tibia and tumor-negative control tibia. In contrast to the 
seemingly paracrine stimulation of the osteoblasts, the induction of osteolysis 
was observed also distant from tumor cells, suggesting endocrine 
communication between the tumor cells and bone. 
Expression of basic bone modulating factors was assessed in the cell lines for 
identification of a potential mechanism behind the decreased bone formation 
and lytic phenotype associated with RGS2 knockdown. The data showed that 
under basic culture conditions, RUNX2 gene expression was up-regulated in 
ShRGS2 compared to ShNT. In line, the RUNX2 regulated PTHrP protein showed 
a trend for increased expression. Additionally, analysis of human specific PTHrP 
in serum from the animal experiment confirmed that both ShRGS2 and ShNT 
tumors expressed the protein. However, there was a non-significant trend 
towards increased levels of PTHrP in ShRGS2 compared to the control. This is in 
line with high RUNX2 level in association with increased PTHrP expression and 
lytic properties of breast and PC cells [198, 203, 204]. Taken together, these 
data suggest an important regulatory role for tumor cell associated RGS2 
expression in association to the sclerotic phenotype of PC bone metastasis. 
Moreover, RGS2 expression in osteoblasts was evaluated with IHC in the 
patient material. Data showed that there was an increased level of RGS2 in in 
osteoblasts from mCRPC compared to mHNPC, in line with elevated levels of 
PTHLH. Together with described osteoblast stimulating effect of RGS2 in 
response to PTHrP signaling [246], this emphasizes the importance of 
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osteoblast associated RGS2 for conservation of the sclerotic phenotype of PC 
bone metastases under high PTHLH conditions. 
The expression of RGS2 in osteoblasts was further assessed, in association to 
castration and different tumor cell associated osteogenic properties. This was 
performed by intratibial implantation of LNCaP, that grow poorly in non-
castrated bone, and LNCaP-19 that has extraordinary ability to form 
osteoblastic tumors in both the castrated and non-castrated state [276]. The 
data showed RGS2 expression was increased in osteoblasts in LNCaP derived 
tumors from castrated mice compared to non-castrated. However, this variance 
was not observed in LNCaP-19 derived tumors, where osteoblasts from 
castrated and non-castrated animals displayed RGS2 levels corresponding to 
the expression seen in LNCaP tumors developed in castrated animals. This 
emphasizes that high RGS2 expression is associated with active osteoblasts in 
association with bone stimulating PC tumor cells. 
In conclusion, the present study suggests that RGS2 has a dual and complex 
regulatory function in PC bone metastases. RGS2 is highly expressed in the 
epithelial cells with induced expression in the dedifferentiated tumor cells of 
mCRPC. Additionally, the data suggests that RGS2 is important for the tumor 
establishment in bone and contribute to the sclerotic phenotype of bone 
metastases, possibly to some extent by regulation of the expression of PTHrP 
and RUNX2. Furthermore, high levels of RGS2 in active, tumor-associated 
osteoblasts suggest the importance of RGS2 for conservation of the sclerotic 
phenotype of PC bone metastases. 
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5 GENERAL DISCUSSION 
PC is often a slow-growing and symptom-free disease with good prognosis. 
However, there is a proportion that will progress and metastasize. Importantly, 
the survival rate drops significantly once the PC is no longer confined in the 
prostate or surrounding tissue [282]. Furthermore, considering bone metastatic 
PC and CRPC, they both represent incurable stages of PC associated with poor 
quality of life [78, 79, 83, 177, 178].  
So, how can one distinguish the good from the bad? And how does one treat 
the incurable? 
 Lack of biomarkers 5.1
A large problem in the field of PC is the lack of reliable biomarkers for diagnosis, 
with ability to distinguish between indolent and aggressive forms.  
PSA is the primary biomarker used in the clinic for monitoring PC. The declined 
mortality observed over the last decades could at least in part be credited to 
the introduction of PSA testing, hence early detection of PC [20]. However, PSA 
as a biomarker has its limitations regarding both sensitivity and specificity. 
Thus, PSA is insufficient for treatment and disease monitoring especially at late 
stages of PC [71]. Despite the shortcomings of PSA, both CRPC patients and 
patients with metastatic disease are continuously monitored with PSA testing, 
with the addition of assessment of performance status and bone associated 
factors [alkaline phosphatase (ALP), bone pain and extent of disease on bone 
scan] [283]. The common drawback of these additional tools is that they are 
generally detectable first at an already advanced stage.  
Metastasized and castration-resistant PC both represents incurable stages of PC 
despite life-prolonging therapeutic advancements in recent years, as therapy 
ultimately fails and a highly aggressive PC emerge that are unresponsive to any 
available treatment [79, 83]. This emphasizes the need for markers that are 
able to indicate relapse at an early stage and suggest for additional drug 
targets, for early eradication and prevention of progress. Thus, there is an 
urgent need for complementing new biomarkers to improved diagnosis and 
treatment decisions. 
 The multifaceted role of RGS2 5.2
To understand the biological processes involved in tumor progression and 
acquisition of treatment-resistance is essential for the development of curative 
treatments and good biomarkers. The progression of PC includes oncogenic 
aberrations in several signaling pathways e.g. AR, HIF1, PI3K/AKT and IL-6/STA3 
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pathways that together induce tumor progression and adaption to treatment 
by intricate interplay [145-150]. In this section follows a general discussion 
regarding findings presented in paper I-IV in the light of what is known about 
RGS2, described in the introduction, and general biological processes. This 
should be looked at as an addition to the discussion in the papers. 
 The impact of a hypoxic environment 5.2.1
Descriptions of the association between hypoxia and EMT/metastasis is not 
straight forward, there are experimental studies that suggests that hypoxia 
induces a partial EMT, not necessarily associated with increased but rather 
decreased tumor cell motility [157, 158]. This is in agreement with the 
observation made in paper I, and rationalizes an association between hypoxia 
suppressed RGS2 expression, and the indolent phenotype and EMT-like 
expression profile acquired in response to RGS2 knockdown. Furthermore, the 
observed induction of BCL-2, is in line with a hypoxia induced resistance-
mechanisms such as up-regulation of anti-apoptotic proteins, including BCL-2 
[151, 152]. However, hypoxia is highly associated with tumor progression 
metastasis and poor clinical outcome [138, 139]. This is logical, considering that 
tumor cells at an exceptionally hypoxic environment would either, develop 
resistance, disseminate or capitulate [145, 284]. The in vivo data suggest that 
RGS2 expression is induced at highly hypoxic areas. Rationalizing this finding, in 
the light of described modes of action for RGS2 and the experimental results 
presented in paper I, one could suggest that this up-regulation is representative 
of two biological processes – apoptosis and metastasis. Interestingly, a both 
protective and promoting role has been described for RGS2 in association with 
apoptosis [255, 258]. Also, in this context is the transcription-regulatory role for 
RGS2 in association to HIF1 highly relevant, especially considering the described 
anti-apoptotic effects [259]. Taken together this may suggest that RGS2 is 
closely involved in HIF1 regulated determination of cell fate. 
 PI3K/AKT 5.2.2
Positive correlation between RGS2 and pAKT observed in the PC patient 
material (Paper III), and the attenuating effect on AKT activation in response to 
RGS2-knockdown (Paper I), collectively suggests that RGS2 may have a positive 
regulatory role for AKT phosphorylation in PC. A reasonable explanation for this 
observation could be via the attenuating influence of RGS2 on Gαq signaling. 
The reported effects on AKT phosphorylation in association with both Gq 
signaling [232-235] and RGS2 [235-237] is somewhat inconsistent. However, 
with reference to the innate preference of RGS2 for Gaq inhibition [229, 230], 
this could describe a mechanism by which RGS2 influence the phosphorylation 
of AKT. Considering that the attenuating effect of Gαq is mediated via 
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interaction with PI3K [232, 233], suggests that such association would have 
relevance especially in PC, where silencing of PTEN is frequently occurring in 
association to PC progress and metastasis [167-169]. 
 STAT3 5.2.3
The less metastatic phenotype observed in response to RGS2 knockdown could, 
at least partly, be ascribed to decreased AKT activity. In addition, knockdown of 
STAT3 in the LNCaP cell line has been shown to induce their metastatic ability 
[119] which suggests that STAT3 has inhibitory effect on metastasis. Moreover, 
nuclear staining of active STAT3 has been shown to be inversely correlated with 
development of metastasis in prostate cancer [285]. This suggests that the 
induced STAT3 expression contributes to the less metastatic phenotype 
observed in response to RGS2 knockdown.  
G-proteins regulatory role of transcription and translation [286, 287], suggests 
a general mechanism by which RGS2 could affect the level of STAT3. However, 
RGS2 ability to directly interact with transcription factors and regulate their 
activity [259, 260] could also be responsible for the increased level of STAT3 
associated with RGS2 knockdown.  
 RGS2 and proliferation  5.2.4
The association between RGS2 knockdown and decreased proliferation suggest 
that RGS2 has a positive regulatory role for cell division. This is in line with the 
earliest reports of RGS2, where RGS2 expression was shown to be induced by 
mitogens in lymphocytes, and thought to be associated with resumed cell 
division [223-225]. The regulatory role for RGS2 could be mediated indirectly 
via the attenuation of the Gaq inhibitory effect on PI3K/AKT (as discussed 
above). In addition, the regulation could be direct, associated with the 
stimulating interaction between RGS2 and polymerizing microtubule [263]. The 
consequence of this direct interaction is accentuated by the significant mitotic 
delay associated with RGS2 knockdown in HeLa cancer cells [265].  
 AR and RGS2 5.2.5
(Paper II) Prostate cancer is generally an AR driven malignancy also at the 
castration-resistant state, where resumed AR signaling is achieved by numerous 
mechanisms [4, 79]. In addition to the clinical relevance suggested for RGS2, 
the data collectively suggests that RGS2 is indicative of resumed or persistent 
AR signaling. The significance of this is perhaps most important considering 
RGS2 expression in association to early ADT, and its association to failure-free 
survival, where RGS2 could be indicative inadequate treatment at a stage 
where fast intervention could have significance for patient outcome.  
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Association between RGS2 and AR/AR signaling has previously been assessed to 
some extent. Related to our observations, has fast induction of RGS2 
expression been associated with AR stimulation, both via traditional ligand 
binding and by antagonist stimulation of a mutated AR [288]. Furthermore, 
down-regulation of RGS2 in response to androgen depletion in vitro has been 
suggested as a mechanism behind acquisition of castration-resistance, related 
to RGS2 attenuating effect on Gq associated androgen-independent activation 
of the AR. However, the inhibitory effect on AR activity was abolished in the 
presence of androgens suggesting that only androgen-independent signaling 
was inhibited [269]. We recapitulated the data showing that RGS2 was down-
regulated in hormone-starved LNCaP, during transition into the castration-
resistant LNCaP-19, and furthermore showed that castration-levels of DHT, 
ample to stimulate AR, was enough to antagonize the suppression of RGS2 
expression that was associated with full hormone-depletion. However, the 
clinical relevance of this finding could be questioned, in light of the generally 
high expression of RGS2 after ADT and persistent high levels of RGS2 in CRPC. 
Especially, considering that full androgen-deprivation is hard to achieve in man, 
allowing for adrenal androgen contribution and  intratumoral steroidogenesis 
[79]. Moreover, it should be noted that LNCaP-19 grows poorly under 
conditions were hormones are available, and it has previously been suggested 
that induced RGS2 level is a part of a suppressive expression profile for LNCaP-
19 derived tumors under these conditions [268].  This suggests that tumor cells 
that acquired castration-resistance by down-regulation of RGS2 would be 
inhibited under typical CRPC tumor conditions.  
 RGS2 and Stress 5.2.6
With reference to RGS2 as a suggested stress-response protein [252, 253], and 
bearing in mind under which orthotopic experimental conditions RGS2 is highly 
expressed - that is under conditions with good oxygen/nutrient supply or under 
extreme hypoxic pressure adjacent necrotic areas - it could be speculated that 
high levels of RGS2 in the clinical specimens subjected to ADT, would signify 
cells that displayed signs of extraordinary stress compared to low expressing 
cells. Theoretically, this could be true and would than suggest a better 
treatment response. However, in light of the patient outcome in terms of 
significantly reduced time to relapse, high levels of RGS2 after ADT would 
rather be indicative of viable cells.  
 RGS2 in bone metastases 5.2.7
The high frequency of PC bone metastases together with its poor prognosis and 
major impact on the patients’ quality of life [177, 178], emphasizes the 
importance of studies in this field. Although rgs2-/- mice lack of an apparent 
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skeleton associated phenotype [245], we did see general and high RGS2 
staining of osteoblasts in our experimental mouse models (tumor negative and 
positive) as well as in the clinical patient material. High levels of RGS2 were also 
evident for the tumor cells. Taken together with the apparently stimulatory 
interaction between RGS2 expressing tumor cells and osteoblast, and the 
hampered ability for cells with RGS2-knockdown to populate the bone – it is 
tempting to speculate about osteomimicry, which has been described to 
enhance tumor cells ability to populate the bone niche (reviewed in [182]). On 
that note, high expression of RGS2 in association to metastasis would also, 
speculatively, imply that cells with high RGS2 expression would have preference 
for homing to the bone. Additionally, it should be mentioned that the 
osteotropic, bone stimulating LNCaP-19 cell line, that express low levels of 
RGS2 in comparison to LNCaP in vitro, significantly up-regulates RGS2  to 
comparable levels when implanted intratibially.  
 RGS2 as a biomarker  5.2.8
The treatment strategies for metastatic disease and CRPC are changing as new 
drugs are introduced in the clinic. However, for best treatment results it is 
essential to know when a certain treatment would be effective and/or in 
combination with which other drug. Therefore, reliable biomarkers are highly 
valuable.  
In the present thesis, RGS2 was identified as a negative prognostic marker in 
both advanced HNPC and CRPC. The high expression of RGS2 after ADT in 
association with short failure-free survival, suggest that RGS2 has a significant 
value as a treatment-predictive biomarker, indicative of patients that would 
benefit from early inception of additional therapy such as anti-androgens, 
chemotherapy or radiation. 
Regardless of the potentially promising value of RGS2 as a biomarker, there are 
some concerns.  
For example, a problem with a tissue confined biomarker, opposing a secreted 
marker, is the availability. However, on the endorsing side, with a tissue-based 
marker the disease is assessed locally with low risk of detecting unassociated 
systemically demonstrated changes.  
Furthermore, although promising prognostic value in paper I and II, RSG2 did 
not prevail as a prognostic marker for HNPC in paper III. There could be several 
reasons for this. This could indicate that epithelial RGS2 is in fact not a 
prognostic marker for HNPC. However, this discrepancy could also describe 
methodological differences. 
Primarily, the methods used for IHC scoring are different. While scoring in 
paper I and paper II give emphasis to intensity, the scoring in paper III 
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emphasizes on distribution. The expression of RGS2 in tumor epithelial cell is 
rather heterogeneous with regular local differences –subpopulations, but also 
scattered differences in intensity. The scoring that was performed in paper III, 
exclude the influence of populations with lower distribution than the majority. 
Whilst the scoring carried out in paper I-II, takes in account the contribution of 
all populations. In the majority of cases, the score would be essentially the 
same - however at the extremes (extremely high or low intensity) the different 
scoring methods will affect the overall total score. Considering that a smaller 
population, observed at a certain time point, could be the growing population 
and have high penetrance at a later stage, one could suggest that it is 
important to consider not only the main intensity and/or the distribution. 
Furthermore, this would imply that the intensity is especially important 
regarding scoring of tumor epithelial cells. However, for scoring of the 
homogenous stroma, distribution is a fitting approach.  
Moreover, there is an important difference in the clinical material assessed for 
RGS2 expression, the material in paper I is comprised of advanced PC, where 
the patient required immediate ADT, while the material included in paper III is 
mixed, with no information regarding subsequent treatment. This could suggest 
that the prognostic properties of RGS2 in HNPC, is actually related to the 
treatment predictive property suggested in paper II. However, since there was 
neither correlation between expression before and after ADT, or association 
between RGS2 expression after initiated ADT and cancer-specific survival (only 
failure-free survival), this is not likely.  
 Future perspectives and concluding remarks 5.2.9
This thesis describes a relevant tumor-promoting role for RGS2 in the 
development of advanced PC and bone metastases, which is worth further 
exploration, considering, the herein suggested discriminating role for RGS2 in 
association to AKT/PI3K and STAT3 signaling. This is especially relevant with 
reference to high prevalence of aberrations in the PI3K/AKT pathway 
associated with progressed disease [120, 122, 125, 126] and the correlation 
between RGS2 and pAKT (paper III). To consider RGS2 as a biomarker, this could 
suggest that RGS2 expression level would be indicative of treatment-windows 
for combination therapy with ADT and PI3K/AKT or IL-6/STAT3 inhibitors. 
Additionally, the phenotype acquired in association with RGS2 knockdown 
compared to RGS2 expressing cells, is in line with the identification of RGS2 as a 
negative prognostic marker for PC, although this was not confirmed in paper III 
(discussed above).  
Moreover, the association between high levels of RGS2 and rapid treatment-
failure is worth further consideration with reference to the highly aggressive 
form of PC that are promoted by ADT [86, 87]. Early detection of resistance, 
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before CRPC establishment, would be valuable considering potential to hinder, 
or at best eradicate, progressing cells. This is especially important considering 
the increased risk for metastatic disease in association with prolonged 
castration-therapy [181, 289-292].  
Finally, the high prevalence of RGS2 in PC bone metastases calls for further 
investigation. The hampering effect of RGS2 knockdown on tumor 
establishment in the bone is especially relevant from a clinical perspective. 
The data suggests that RGS2 has potential as prognostic and treatment-
predictive biomarker in PC. However, further evaluation of the prognostic and 
predictive value of RGS2 is required to ascertain the significance of these 
findings.  
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6 CONCLUSIONS 
The following conclusions were based on results and data included in the 
present thesis 
• RGS2 expression is generally decreased in indolent hormone-
naïve PC compared to benign prostate tissue  
 
• Moderate hypoxia suppresses RGS2 expression while 
extreme hypoxia induce RGS2 expression in PC cells 
 
• RGS2 is generally highly expressed in advanced PC in 
association with an aggressive tumor phenotype 
 
• RGS2 appears to be involved in fundamental biological 
processes associated with PC progression 
 
• High epithelial RGS2 expression is selected for during 
androgen deprivation therapy and is indicative of resumed 
AR activity and imminent castration-resistant relapse  
 
• Stromal RGS2 expression is decreased in PC in association 
with increasingly advanced disease 
 
• Tumor cell associated RGS2 expression contributes to the 
development of PC bone metastases  
 
• Both epithelial and stromal RGS2 expression may have clinical 
value for detection of advanced prostate cancer 
 
• Epithelial RGS2 expression has potential as a treatment-
predictive biomarker for ADT 
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